

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-10 8-9 9-12 10-11 11-12

exact/norm bonds :

5-7 6-9 7-8 7-10 8-9 9-12 10-11 11-12

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom

Aryl Fused Azapolycyclic Compounds

=> d his

(FILE 'HOME' ENTERED AT 14:38:57 ON 14 MAY 2004)

FILE 'REGISTRY' ENTERED AT 14:39:09 ON 14 MAY 2004

L1 STRUCTURE UPLOADED
L2 QUE L1
L3 1 S L2
L4 100 S 230615?/RN
L5 578891 S 5-6-6/SZ
L6 105840 S 5-5-6-6/SZ
L7 384378 S 5-6-6-6/SZ
L8 4152 S 4-5-6-6/SZ
L9 22481 S 5-6-6-7/SZ
L10 65762 S 5-5-6-6-6/SZ
L11 1158175 S L5 OR L6 OR L7 OR L8 OR L9 OR L10
L12 2 S L2 SUB=L11 SAM
L13 366 S L2 SUB=L11 FUL

FILE 'CAPLUS' ENTERED AT 14:47:17 ON 14 MAY 2004

L14 23 S L13

FILE 'REGISTRY' ENTERED AT 14:47:39 ON 14 MAY 2004

FILE 'CAOLD' ENTERED AT 14:48:24 ON 14 MAY 2004

L15 0 S L13

FILE 'CAPLUS' ENTERED AT 14:48:31 ON 14 MAY 2004

FILE 'REGISTRY' ENTERED AT 14:49:37 ON 14 MAY 2004

L16 STRUCTURE UPLOADED
L17 QUE L16
L18 2 S L17 SUB=L11 SAM
L19 370 S L17 SUB=L11 FUL
L20 4 S L19 NOT L13

FILE 'CAPLUS' ENTERED AT 14:50:49 ON 14 MAY 2004


L21 14 S L20
L22 23 S L14 OR L21

=> d 12

L2 HAS NO ANSWERS

L1 STR

A



Structure attributes must be viewed using STN Express query preparation.


Aryl Fused Azapolycyclic Compounds

L2 QUE ABB=ON PLU=ON L1

=> d l17

L17 HAS NO ANSWERS

L16 STR



Structure attributes must be viewed using STN Express query preparation.

L17 QUE ABB=ON PLU=ON L16

=> d ibib abs hitstr 1-23

L22 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2004 ACS ON STN
ACCESSION NUMBER: 2004:80526 CAPLUS
DOCUMENT NUMBER: 140:144688
TITLE: Hapten-carrier conjugates comprising hormone, toxin,
or drug for diagnosis and therapy
INVENTOR(S): Bachmann, Martin F.; Maurer, Patrik
PATENT ASSIGNEE(S): Cytos Biotechnology Ag, Switz.
SOURCE: PCT Int. Appl., 144 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009116	A2	20040129	WO 2003-EP7850	20030718
WO 2004009116	A3	200404138		
W:	AE, AG, AL, AM, AN, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FG, GD, GE, GH, GM, HR, HU, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, AZ, AY,			
RW:	KG, KZ, MD, RU, CH, GM, KE, MG, MN, MW, MX, NZ, SD, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CA, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,			
	WI, MT, MR, NE, SN, TD, TG			

PRIORITY APP4059094 A1 20040325 US 2003-622064 20030718
 AB The present invention provides compns. comprising a conjugate of a hapten
 with a carrier in an ordered and repetitive array, and methods of making
 such compns. The conjugates and compns. of the invention may comprise a
 variety of haptens, including hormones, toxins and drugs, especially drugs
 of addition such as nicotine. Compns. and conjugates of the invention are
 useful for inducing immune responses against haptens, which can use useful
 in a variety of therapeutic, prophylactic and diagnostic regimens. In
 certain embodiments, immune responses generated by the invention may comprise
 compns. and methods of the present invention are useful to prevent or
 treat addiction to drugs of abuse and the resultant diseases associated with
 drug addiction.
 IT 249296--44-4D, Valencicline, salts and optical isomers
 375015-07-S, Valencicline tartrate
 At. num. (Analyte): HSU (Biological study, unclassified); DGN (Diagnostic
 use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological
 study); USES (Uses)
 (hapten-carrier conjugates comprising a hormone, toxin, or drug and a
 core particle of bacteriophage protein for diagnosis and therapy)
 RN 249296-44-4 CAPLUS
 CN 6,10-Methyleno-6H-pyrazino[2,3-b] [3] benzazepine, 7,8,9,10-tetrahydro- (9CI)
 (CA INVENTION)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:622565 CAPLUS
DOCUMENT NUMBER: 139:179986
TITLE: Preparation of aryl-fused azapolycyclic compounds for
reducing nicotine addiction
INVENTOR(S): Cos, Jotham Wadsworth Brooks, Paige Roanne Palmer
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S., 39 pp., Cont.-in-part of Appl. No.
PCT/IB98/01813.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 66005610	B1	20030812	US 2000-514002	20000225
US 9935131	A1	19990715	WO 1998-181813	19981113
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GR, HU, ID, IL, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, LY, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RU, SD, SE, SG, SI, SK, SL, SR, TH, TT, UG, US, UZ, VU, ZW, AM, AZ, BA, BG, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, CA, GN, GW, ML, HR, NE, SN, TD, TG				
US 6140550	B1	20020625	US 1999-402010	19990928
WO 2001062736	A1	20010830	WO 2001-18153	20010208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CR, CU, DE, EE, ES, FI, FR, GB, GE, GH, GM, GR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LV, LU, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TR, TT, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, T2, UJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SZ, UG, PT, AE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GW, ML, HR, NE, SN, TD, TG				
BR 200106810	A1	20021115	EP 2001-8610	20010208
EP 1259489	A1	20021127	EP 2001-953630	20010208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 200324002	T2	20030812	JP 2001-562518	20010208
EE 20020475	A	20031215	EE 2002-475	20010208
BG 106908	A	20030430	BG 2002-106908	20020705
ZA 200200676	A	20030822	ZA 2002-676	20020822
NO 200204042	A	20021011	NO 2002-4042	20020822
US 2003130261	A1	20030710	US 2003-336508	20030103
US 2003130260	A1	20030710	US 2003-336532	20030103


US 2003130260	A1	2003/10	09/20/93-356532	
PRIORITY APPLN. INFO.:			US 1997-70245P	P 19971231
			WO 1998-1B1813	A2 19981113
			US 1999-402010	A2 19990928
			US 2000-514002	A 20000225
			WO 2001-1B153	W 20010208
OTHER SOURCE(S):		MARPAT 139:1799#6		
GI				

C1CN2C(=N1)C3=CC=CC=C3C2

RN 375815-87-5 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-,
(2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 249296-44-4
CMF C13 H13 N3



CM 2

CRN 87-69-4
CMF C4 H6 06

Absolute stereochemistry.




AB The invention discloses the preparation of aryl-fused azapolycyclic compounds, such as I [$\text{R}^1 = \text{H, alkyl, unconjugated alkenyl, benzyl, CO(R)}, \text{R}^2 = \text{CH}_2\text{CH}_2\text{-alkyl, R}^3 = \text{H, alkenyl, alkynyl, OH, NO}_2, \text{NH}_2, \text{halo, CN, etc.}$ or R^2 and R^3 , together with the carbons to which they are attached, form a 4-7 membered monocyclic ring or a 10-14 membered bicyclic ring] $\text{R}^4 = \text{H, alkyl; X = alkylene}$ and their pharmacologically acceptable salts, as nicotine binding inhibitors (IC₅₀ $< 10^{-6}$ M) and as antitumor and psychol. agents. Thus, aryl-fused azapolycyclic compound I ($\text{R}^1 = \text{R}^3 = \text{H}$), was prepared via a multistep synthetic sequence starting from


IT 230615-08-4P 328055-86-3P 328055-99-8P
357424-19-2P 357424-20-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aryl-fused azapolycyclic compds. as nicotine binding inhibitors)

RN 230615-08-4 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7,8-dinitro- (9CI) (CA
 INDEX NAME)




RN 328055-86-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)




RN 328055-99-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA
INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 357424-19-2 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-b][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 357424-20-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)




IT 69718-72-5P 230614-99-0P 230615-00-6P
230615-01-7P 230615-02-8P 230615-03-9P
230615-04-0P 230615-05-1P 230615-06-2P
230615-07-3P 230615-09-5P 230615-10-8P
230615-11-9P 230615-12-0P 230615-13-1P
230615-14-2P 230615-15-3P 230615-16-4P
230615-17-5P 230615-18-6P 230615-19-7P
230615-20-0P 230615-21-1P 230615-22-2P
230615-23-3P 230615-24-4P 230615-25-5P
230615-26-6P 230615-27-7P 230615-28-8P
230615-29-9P 230615-30-2P 230615-31-3P
230615-32-4P 230615-33-5P 230615-34-6P
230615-35-7P 230615-36-8P 230615-37-9P
230615-38-0P 230615-39-1P 230615-40-4P
230615-41-5P 230615-42-6P 230615-43-7P
230615-44-8P 230615-45-9P 230615-46-0P
230615-75-5P 357425-82-2P 357425-83-3P
357425-84-4P 357425-86-6P 357425-87-7P
357425-88-8P 357425-89-9P 357425-90-2P
357425-91-3P 357425-92-4P 357425-93-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of aryl-fused azapolycyclic compds. as nicotine binding

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 69718-72-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 230614-99-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-00-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-01-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl

RN 230615-02-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-03-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 6-fluoro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-04-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-05-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-amine, 2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-06-2 CAPLUS
CN Acetamide, N-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-07-3 CAPLUS
CN 5,9-Methano-5H-thiazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 230615-09-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-10-8 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-11-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-12-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-16-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-17-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-18-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-13-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-14-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-15-3 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-19-7 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-20-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-1,5,6,7,8,9-hexahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-21-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-b][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-22-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-23-3 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-24-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-25-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-26-6 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-27-7 CAPLUS
CN Benzamide, 2-fluoro-N-(2,3,4,5-tetrahydro-8-hydroxy-1,5-methano-1H-3-benzazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-28-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-29-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-30-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-31-3 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-32-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-33-5 CAPLUS
CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-34-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-5-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-35-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-36-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-40-4 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-41-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-42-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-6-ol, 2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-37-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-38-0 CAPLUS
CN Pyrrolidine, 1-[(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-39-1 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-43-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-44-8 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 2-ethyl-6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-45-9 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-46-0 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-75-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 357425-82-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● 2 HCl

RN 357425-88-8 CAPLUS
CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepine-2-one, 1,6,7,8,9,10-hexahydro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 357425-89-9 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 357425-90-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 357425-83-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 357425-84-4 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 357425-86-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 357425-87-7 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 357425-91-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-5-fluoro-7,8,9,10-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 357425-92-4 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepine-2-one, 1,6,7,8,9,10-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 357425-93-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)

CH 1

CPN 69718-72-5
CMF C11 H13 N


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CN 2

CRN 104-15-4
CMF C7 H8 O3 S




IT 230615-52-8 357426-15-4 357426-16-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aryl-fused azapolycyclic compds. as nicotine binding inhibitors)
RN 230615-52-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 357426-15-4 CAPLUS
CN Ethanethioamide, 2,2,2-trifluoro-N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoro-1-thioxoethyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-51-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-53-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-56-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-amine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-57-3 CAPLUS
CN Acetamide, N-[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 230615-59-5 CAPLUS


Page 9

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 357426-16-5 CAPLUS
CN 5,9-Methano-5H-thiazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




IT 230615-48-2P 230615-50-6P 230615-51-7P
230615-53-9P 230615-56-2P 230615-57-3P
230615-59-5P 230615-60-8P 230615-61-9P
230615-62-0P 230615-63-1P 230615-64-2P
230615-65-3P 230615-66-4P 230615-67-5P
230615-68-6P 230615-69-7P 230615-70-0P
230615-71-1P 230615-72-2P 230615-73-3P
230615-74-4P 230615-77-7P 230615-78-8P
230615-79-9P 230615-80-2P 230615-81-3P
230615-82-4P 230615-83-5P 230615-84-6P
230615-85-7P 230615-86-8P 230615-88-0P
230615-89-1P 230615-92-6P 230615-93-7P
357425-94-6P 357425-95-7P 357425-96-8P
357425-97-9P 357425-98-0P 357425-99-1P
357426-00-7P 357426-01-8P 357426-02-9P
357426-04-1P 357426-05-2P 357426-06-3P
357426-07-4P 357426-08-5P 357426-09-6P
357426-10-9P 357426-13-2P 357426-17-6P
357426-18-7P 357426-19-8P 357426-20-1P
357426-21-2P 357426-22-3P 357426-23-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aryl-fused azapolycyclic compds. as nicotine binding inhibitors)
RN 230615-48-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 230615-50-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7,8-dinitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-60-8 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7,8-dinitro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-61-9 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7,8-diamino-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-62-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-63-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-1-propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-64-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-65-3 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-(butylamino)-1,2,4,5-tetrahydro-8-nitro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-66-4 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-amino-8-(butylamino)-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-67-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 1-butyl-5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-72-2 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-amino-8-(butylamino)-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-73-3 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-74-4 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-77-7 CAPLUS
CN 1,5-Methano-3H-3-benzazepine, 2,3,4,5-tetrahydro-7-iodo-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-68-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-1-(2-methylpropyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-69-7 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-7,8-diamine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-70-0 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-71-1 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-7-ol, 2,3,4,5-tetrahydro-8-nitro-3-


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-78-8 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-iodo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-79-9 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-cyano-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-80-2 CAPLUS
CN 1,5-Methano-3H-3-benzazepine, 7-acetyl-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-81-3 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-acetyl-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




Aryl Fused Azapolycyclic Compounds

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 230615-82-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)-, acetate (ester) (9CI) (CA INDEX NAME)




RN 230615-83-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-84-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 8-acetyl-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-85-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-8-[1-(hydroxyimino)ethyl]-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-phenyl-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 357425-94-6 CAPLUS
CN Ethanethioamide, N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoro-1-thioxoethyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 357425-95-7 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 2-chloro-6,7,8,9-tetrahydro-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357425-96-8 CAPLUS
CN Boronic acid, [2,3,4,5-tetrahydro-3-(phenylmethyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 357425-97-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 230615-86-8 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-88-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-89-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonyl chloride, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-92-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-iodo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 230615-93-7 CAPLUS


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-98-0 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357425-99-1 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-00-7 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-01-8 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




Aryl Fused Azapolycyclic Compounds

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 357426-02-9 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-04-1 CAPLUS
CN Propanamide, 3,3-dimethoxy-N-[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 357426-05-2 CAPLUS
CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-06-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-07-4 CAPLUS

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 1,5-Methano-2H-3-benzazepin-2-one, 1,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357426-17-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 1-(2,2-dimethylpropyl)-5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 357426-18-7 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 1-(2,2-dimethylpropyl)-5,6,8,9-tetrahydro-2-methyl-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 357426-19-8 CAPLUS
CN 6,10-Methano-8H-pyrazino[2,3-h][3]benzazepine-8-carboxylic acid, 6,7,9,10-tetrahydro-2,3-dimethyl-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 6,10-Methano-8H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid, 2-chloro-6,7,9,10-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 357426-08-5 CAPLUS
CN 6,10-Methano-8H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid, 6,7,9,10-tetrahydro-2-methoxy-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 357426-09-6 CAPLUS
CN 6,10-Methano-8H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid, 2-chloro-5-fluoro-6,7,9,10-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)




RN 357426-10-9 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-13-2 CAPLUS

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl


RN 357426-20-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carboximidamide, 2,3,4,5-tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 357426-21-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-[3-(dimethylamino)-1-oxo-2-propenyl]-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-22-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-23-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-pyrrolidinylsulfonyl)-3-(trifluoroacetyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
INDEX NAME)




● HCl

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:434575 CAPLUS
DOCUMENT NUMBER: 139:966
TITLE: Aryl fused azapolycyclic compounds for the treatment of nicotine addiction/withdrawal and CNS disorders
INVENTOR(S): Obach, Ronald Scott; Hagen, Anne Elizabeth
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045967	A1	20030605	WO 2002-IB4820	20021118
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p> <p>RW: GH, GM, KE, LS, MV, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				
US 2003166582	A1	20030904	US 2002-306500	20021127
PRIORITY APPL. INFO.:		US 2001-334502P P 20011130		
OTHER SOURCE(S):		MARPAT 139:966		
GI				




AB The invention discloses aryl fused azapolycyclic compds. I [R1 = H, COOR4

L22 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(R4 = Q1, Q2); R2, R3 = bicyclic ring system-forming moieties, etc.), and their pharmaceutically acceptable salts; intermediates for the synthesis of such compds.; and methods of using such compds. in the treatment of nicotine addiction/withdrawal and CNS disorders. The tetrahydromethanobenzazepine derivs. of the invention bind to neuronal nicotinic acetylcholine receptor sites and are useful in modulating cholinergic function.
IT 249296-44-4 357424-21-6 535920-98-0
RI: BSU (Biological study, unclassified); PKT (Pharmacokinetics); BIOL (Biological study)
(aryl fused azapolycyclic compds. for treatment of nicotine addiction/withdrawal and other disorders)
RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-21-6 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro- (9CI) (CA INDEX NAME)



RN 535920-98-0 CAPLUS
CN β-D-Glucopyranuronic acid, 1-(6,7,9,10-tetrahydro-6,10-methano-8H-pyrazino[2,3-h][3]benzazepin-8-carboxylate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 69718-72-5D, deriva.
RI: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aryl fused azapolycyclic compds. for treatment of nicotine addiction/withdrawal and other disorders)
RN 69718-72-5 CAPLUS

L22 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:43404 CAPLUS
DOCUMENT NUMBER: 139:12305
TITLE: Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
INVENTOR(S): Am Ende, Mary Tanya; Roy, Michael Christopher; Smith, Scott Wendell; Waterman, Kenneth Craig; Moses, Sara Kristen; Quan, Ernest Shing
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045437	A1	20030605	WO 2002-IB4612	20021104
WO 2003045437	C1	20030814		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003180360	A1	20030925	US 2002-300608	20021120
PRIORITY APPLN. INFO.: US 2001-334652P P 20011130				
GI				




AB The present invention is directed to controlled-release (CR) oral pharmaceutical dosage forms of I and pharmaceutically acceptable salts thereof, and methods of using them to reduce nicotine addiction or aiding in the cessation or lessening of tobacco use while reducing nausea as an adverse effect. The present invention also relates to an immediate-release (IR) low dosage composition having a stable formulation with uniform drug distribution and potency. Controlled-release tablets of I L-tartrate were prepared
IT 249296-44-4 375015-87-5 536696-70-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)

L22 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2
CRN 77-92-9
CMF C6 H8 O7



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L22 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

1)-hexadeca-2(11)3,5,7,9-pentaene)
RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 375015-87-5 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1
CRN 249296-44-4
CMF C13 H13 N3



CM 2
CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 536696-70-5 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1
CRN 249296-44-4
CMF C13 H13 N3

L22 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:434372 CAPLUS
DOCUMENT NUMBER: 139:12300
TITLE: Preparation of triazatetracyclooctaene succinate for pharmaceutical compositions
INVENTOR(S): Quallich, George Joseph; Wint, Lewin Theophilus
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045394	A1	20030605	WO 2002-IB4380	20021021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, NO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003149044	A1	20030807	US 2002-305845	20021127
PRIORITY APPLN. INFO.: US 2001-334245P P 20011129				

AB The present invention is directed to the 5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-pentaene succinate salt (I) and pharmaceutical compns. thereof. The invention is also directed to a process for preparation of the salts. Thus, I was prepared by the reaction of the free base with succinic acid in 2-ProH. The compound was characterized by x-ray diffraction studies.

IT 535959-68-3P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of triazatetracyclooctaene succinate for pharmaceutical compns.)

RN 535959-68-3 CAPLUS
CN Butanedioic acid, compd. with 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine (1:1) (9CI) (CA INDEX NAME)

CM 1
CRN 249296-44-4
CMF C13 H13 N3




Aryl Fused Azapolycyclic Compounds

L22 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CM 2

CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

IT 535959-69-4P
RL: PR (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazatetracyclooctaene succinate for pharmaceutical
comps.)
RN 535959-69-4 CAPLUS
CN Butanedioic acid, compd. with 7,8,9,10-tetrahydro-6,10-methano-6H-
pyrazino[2,3-h][3]benzazepine (1:1), hydrate (9CI) (CA INDEX NAME)
CM 1
CRN 249296-44-4
CMF C13 H13 N3



CM 2
CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

IT 249296-44-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of triazatetracyclooctaene succinate for pharmaceutical
comps.)
RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI)
(CA INDEX NAME)



L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:356250 CAPLUS
DOCUMENT NUMBER: 138:348736
TITLE: Nicotinic acetylcholine receptor agonists in the
treatment of restless legs syndrome
INVENTOR(S): Saltarelli, Mario David
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003037329	A1	20030508	WO 2002-184379	20021021
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, CA, CH, CN, CU, CR, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003134844	A1	20030717	US 2002-224055	20020820
PRIORITY APPLN. INFO.:			US 2001-334810P	P 20011031
			US 2001-335858P	P 20011126


OTHER SOURCE(S): MARPAT 138:348736
AB The invention discloses the use of nicotinic acetylcholine receptor agonists for the treatment of restless legs syndrome (RLS). The invention further discloses the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for the treatment of RLS. The invention also discloses a pharmaceutical composition for the treatment of RLS containing a nicotinic acetylcholine receptor agonist.
IT 69718-72-5 230615-75-5 249296-44-4
287973-26-6 328055-80-7 328055-84-1
328055-85-2 328055-86-3 328055-87-4
328055-88-5 328055-89-6 328055-90-9
328055-92-1 328055-94-3 328055-95-4
328055-96-5 328055-97-6 328055-98-7
328055-99-8 357424-02-3 357424-03-4
357424-04-5 357424-11-4 357424-12-5
357424-13-6 357424-14-7 357424-15-8
357424-16-9 357424-18-1 357424-19-2
357424-20-5 357424-21-6 357424-22-7
357424-23-8 357424-24-9 357424-25-0
357424-26-1 357424-32-9 357424-34-1
357424-36-3 357424-37-4 357424-39-6
357424-41-0 357424-43-2 357424-45-4
357424-47-6 357424-49-8 357424-51-2
357426-16-5 519165-22-1 519165-23-2
519165-24-3 519165-25-4 519165-26-5
519165-27-6 519165-28-7 519165-29-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

L22 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(nicotinic agonists for treatment of restless legs syndrome)
RN 69718-72-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 230615-75-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI)
(CA INDEX NAME)



RN 287973-26-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-80-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-84-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-85-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 328055-86-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)




RN 328055-87-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)




RN 328055-88-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-96-5 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 328055-97-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-98-7 CAPLUS
CN 5,9-Methano-5H-isoaxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)



RN 328055-99-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-02-3 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)


Page 16

L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 328055-89-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)




RN 328055-90-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)



RN 328055-92-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)




RN 328055-94-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-95-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-03-4 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 357424-04-5 CAPLUS
CN Benzamide, 2-fluoro-N-(2,3,4,5-tetrahydro-8-hydroxy-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 357424-11-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-propyl- (9CI) (CA INDEX NAME)




RN 357424-12-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 357424-13-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(9CI) (CA INDEX NAME)




RN 357424-14-7 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



RN 357424-15-8 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 357424-16-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-phenyl- (9CI) (CA INDEX NAME)




RN 357424-18-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Acetamide, N-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 357424-24-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)




RN 357424-25-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 357424-26-1 CAPLUS
CN Pyrrolidine, 1-[(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 357424-32-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-19-2 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)




RN 357424-20-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 357424-21-6 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro- (9CI) (CA INDEX NAME)



RN 357424-22-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-amine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-23-8 CAPLUS

L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 357424-34-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 6-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-36-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-37-4 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 357424-39-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)




RN 357424-41-0 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




Aryl Fused Azapolycyclic Compounds


L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 357424-43-2 CAPLUS
 CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 357424-45-4 CAPLUS
 CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro- (9CI) (CA INDEX NAME)




RN 357424-47-6 CAPLUS
 CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 357424-49-8 CAPLUS
 CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methoxy- (9CI) (CA INDEX NAME)



RN 357424-51-2 CAPLUS
 CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-5-fluoro-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 519165-25-4 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-phenyl- (9CI) (CA INDEX NAME)




RN 519165-26-5 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-6-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 519165-27-6 CAPLUS
 CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 2-ethyl-6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 519165-28-7 CAPLUS
 CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 519165-29-8 CAPLUS


L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357426-16-5 CAPLUS
 CN 5,9-Methano-5H-thiazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 519165-22-1 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 519165-23-2 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 519165-24-3 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

L22 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:23533 CAPLUS
 DOCUMENT NUMBER: 138:83396
 TITLE: Pharmaceutical composition and method of modulating cholinergic function in a mammal
 INVENTOR(S): Coe, Jotham W.; Sands, Steven B.
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 23 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003008892	A1	20030109	US 2002-105605	20020325
WO 2003005998	A2	20030123	WO 2002-181767	20020521
WO 2003005998	A3	20030530		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 NZ 529607 A 20031219 NZ 2002-529607 20020521
 EP 1404320 A2 20040407 EP 2002-727942 20020521
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2001-303957P P 20010709
 WO 2002-181767 W 20020521

AB A composition for modulating cholinergic function in a mammal comprises a nicotinic receptor partial agonist (NRPA) in combination with an anti-emetic/anti-nausea agent and a pharmaceutically acceptable carrier. The NRPA compound and the anti-emetic/anti-nausea agent are present in amounts that render the composition effective modulating cholinergic function or in the treatment of various disorders or conditions selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alc., benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile

L22 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome. The method of using these compna. is also disclosed.
 IT 69718-72-5 249296-44-4 287973-26-6
 287973-27-7 328055-77-2 328055-78-3
 328055-79-4 328055-80-7 328055-81-8
 328055-83-0 328055-84-1 328055-85-2
 328055-86-3 328055-87-4 328055-88-5
 328055-89-6 328055-90-9 328055-92-1
 328055-94-3 328055-95-4 328055-96-5
 328055-97-6 328055-99-0 328056-66-2
 357424-19-2 367511-27-1 367511-30-6
 367511-38-4


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. containing nicotinic receptor partial agonist in combination with antiemetic for modulating cholinergic function)
 RN 69718-72-5 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 249296-44-4 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 287973-26-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 287973-27-7 CAPLUS
 CN 5,9-Methano-1H-3-benzazepine-7-carbonitrile, 8-ethynyl-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-77-2 CAPLUS
 CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 328055-78-3 CAPLUS
 CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



RN 328055-79-4 CAPLUS
 CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-80-7 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-81-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 328055-83-0 CAPLUS
 CN 5,9-Methano-2H-isothiazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 328055-84-1 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



RN 328055-85-2 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 328055-86-3 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)




RN 328055-87-4 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-88-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 328055-89-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)




RN 328055-90-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)




RN 328055-92-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)




L22 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328056-66-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-19-2 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 367511-27-1 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-3(5H)-one, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 367511-30-6 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-3(5H)-one, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 367511-38-4 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(5H)-one, 6,7,8,9-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)

L22 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 328055-94-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-95-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-96-5 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 328055-97-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-99-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)

L22 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



Aryl Fused Azapolycyclic Compounds

L22 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:888737 CAPLUS
DOCUMENT NUMBER: 137:375226
TITLE: The citrate salt of 5, 8, 14-triazatetracyclo[10.3.1.02.11.04.9]-hexadeca-2(11),3,5,7,9-pentane and pharmaceutical compositions thereof
INVENTOR(S): Johnson, Philip James; Rose, Peter Robert; Wint, Lewin Theophilus; Williams, Glenn Robert
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092597	A1	20021121	WO 2002-1B1450	20020426
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1390366	A1	20040225	EP 2002-724553	20020426
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
EE 200300557	A	20040415	EE 2003-557	20020426
US 2003149091	A1	20030807	US 2002-139449	20020506
NO 200305035	A	20031113	NO 2003-5035	20031113
PRIORITY APPLN. INFO.:			US 2001-290863P	P 20010514
			WO 2002-1B1450	W 20020426

AB The present invention is directed to the citrate salt of 5, 8, 14-triazatetracyclo[10.3.1.02.11.04.9]-hexadeca-2(11),3,5,7,9-pentane and pharmaceutical compns. thereof. The present invention is also directed to the various forms for the citrate salt, particularly its hydrate and its anhydrous/nearly anhydrous polymorph. The invention is also directed to processes for preparation of these citrate salt forms.

IT 475478-66-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(citrate salt of azatetracyclohexadecapentaene and pharmaceutical compns. thereof)
RN 475478-66-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1), monohydrate (9CI) (CA INDEX NAME)
CM 1

L22 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:888737 CAPLUS
DOCUMENT NUMBER: 137:375274
TITLE: Preparation of pharmaceutical compositions of tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02.11.04.9]-hexadeca-2(11),3,5,7,9-pentane
INVENTOR(S): Bogle, David Everett; Rose, Peter Robert; Williams, Glenn Robert
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092089	A1	20021121	WO 2002-1B1437	20020426
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1392307	A1	20040303	EP 2002-722625	20020426
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002009605	A	20040323	BR 2002-9605	20020426
EE 200300556	A	20040415	EE 2003-556	20020426
US 2003166701	A1	20030904	US 2002-139730	20020506
NO 200305036	A	20031113	NO 2003-5036	20031113
PRIORITY APPLN. INFO.:			US 2001-290861P	P 20010514
			WO 2002-1B1437	W 20020426

AB The present invention is directed to the tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02.11.04.9]-hexadeca-2(11),3,5,7,9-pentane (I), and their pharmaceutical compns. The present invention in particular is directed to the L-tartrate salt, and further to the various polymorphs of the L-tartrate salt, including 2 distinct anhydrous polymorphs (referred to herein as Forms A and B) and a hydrate polymorph (referred to as Form C). In addition, the present invention is also directed to the D-tartrate salt of I and the various polymorphs as well as the DL-tartrate salt and its polymorphs, and the mesotartrate salt and its polymorphs. Thus, polymorphs of I L-tartrate salt were prepared by the reaction of the drug base with L-tartaric acid in MeOH. The forms were characterized by x-ray diffraction, DSC and spectrometry.


IT 375815-87-5P, CP 526555-18 475470-33-8P 475470-34-9P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. containing polymorphs of tartrate salts of triazatetracyclohexadecapentaene)
RN 375815-87-5 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

L22 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


CRN 249296-44-4
CMF C13 H13 N3



CM 2
CRN 77-92-9
CMF C6 H8 O7



IT 249296-44-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(citrate salt of azatetracyclohexadecapentaene and pharmaceutical compns. thereof)
RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L22 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CM 1
CRN 249296-44-4
CMF C13 H13 N3




CM 2
CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 475470-33-8 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1), monohydrate (9CI) (CA INDEX NAME)

CM 1
CRN 249296-44-4
CMF C13 H13 N3




CM 2
CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 475470-34-9 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-,
rel- (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 249296-44-4
CMF C13 H13 N3




CM 2

CRN 133-37-9
CMF C4 H6 O6

Relative stereochemistry.







IT 249296-44-4, CP 526555
RL: RCT (Reactant); RACT (Reactant or reagent)
(pharmaceutical compns. containing polymorphs of tartrate salts of
triazatetracyclohexadecapentaene)
RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI)
(CA INDEX NAME)



L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:832750 CAPLUS
DOCUMENT NUMBER: 137:337794
TITLE: Process for the preparation of 1,3-substituted indenenes
and aryl-fused azapolycyclic compounds
INVENTOR(S): Singer, Robert Alan; McKinley, Jason Daniel
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085843	A2	20021031	WO 2002-1B660	20020304
WO 2002085843	A3	20030605		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZH, ZW, AM, AZ, BY, KG, KZ, MD, RU, T, TH			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1383733	A2	20040128	EP 2002-701498	20020304
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2003060624	A1	20030327	US 2002-124135	20020417
PRIORITY APPLN. INFO.:			US 2001-285131P	P 20010420
			WO 2002-1B660	W 20020304
OTHER SOURCE(S):		MARFAT 137:337794		
GI				



L22 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AB The 1,3-substituted indenenes I-III [R1 = CN, alkoxy, carbonyl, acyl, aryl, NO2, CF3, sulfonyl; R2, R3 = H, F, Cl, alkylthio, alkylsulfinyl, alkylsulfonyl, (un)substituted NH2, CO2H, CONH2, SO2NH2, alkoxy etc.; R4 = H, ammonium, alkali metal; R5 = alkyl, trialkylsilyl, SiPh3] were prepared as intermediates for the benzazepine derivatives IV which modulate cholinergic function. Thus, 2-BrC6H4CH2CN was treated with MeOCH2CH2CO2Me to give 2-BrC6H4C(CN):CHCH2CO2Me which was cyclized to 3-(hydroxymethoxymethylene)-3H-indene-1-carbonitrile sodium salt. Reductive cyclization of the latter compound gave 2,3,4,5-tetrahydro-1,5-methano-1H-benzazepine-2-one.

IT 230615-04-OP 230615-08-4P 230615-51-7P
230615-52-8P 230615-53-9P 230615-54-0P
230615-55-1P 230615-56-2P 230615-57-3P
230615-58-5P 230615-60-8P 230615-61-9P
230615-62-0P 230615-63-1P 230615-64-2P
230615-65-3P 230615-66-4P 230615-67-5P
230615-68-6P 230615-69-7P 230615-70-8P
230615-71-1P 230615-72-2P 230615-73-3P
230615-74-4P 230615-75-5P 230615-76-6P
230615-77-7P 230615-78-8P 230615-79-9P
230615-80-2P 230615-81-3P 230615-82-4P
230615-83-5P 230615-84-6P 230615-85-7P
230615-86-8P 230615-88-0P 230615-89-1P
249296-44-4P 328055-86-3P 328055-99-8P
357424-20-5P 357424-25-0P 357424-47-6P
357425-94-6P 357425-98-0P 357425-99-1P
357426-00-7P 357426-01-8P 357426-02-9P
357426-04-1P 357426-05-2P 357426-06-3P
357426-07-4P 357426-08-5P 357426-10-9P
357426-21-2P 474024-46-9P 474024-47-0P
474024-48-1P 474024-59-4P
RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1,3-substituted indenenes as intermediates for aryl-fused azapolycyclic compds. with cholinergic function)

RN 230615-04-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 230615-08-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7,8-dinitro- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 230615-51-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-52-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-53-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-54-0 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-nitro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-55-1 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-amino-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-56-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-amine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-57-3 CAPLUS
CN Acetamide, N-[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 230615-59-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7,8-dinitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-60-8 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7,8-dinitro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-61-9 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7,8-diamino-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-62-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-63-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-1-propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-64-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-65-3 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-(butylamino)-1,2,4,5-tetrahydro-8-nitro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-66-4 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-amino-8-(butylamino)-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-67-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 1-butyl-5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-68-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-1-(2-methylpropyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-69-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7,8-diamine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-70-0 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-71-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-ol, 2,3,4,5-tetrahydro-8-nitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-76-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-77-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-iodo-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-78-8 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-iodo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-79-9 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-cyano-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-80-2 CAPLUS


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-72-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-ol, 8-amino-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-73-3 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-74-4 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-75-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-81-3 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-acetyl-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-82-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-ol, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)-, acetate (ester) (9CI) (CA INDEX NAME)




RN 230615-83-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-ol, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-84-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-ol, 8-acetyl-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-85-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-8-[1-(hydroxyimino)ethyl]-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-86-8 CAPLUS
CN 5,9-Methano-5H-isoaxazolo[4,5-b][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-88-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-89-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonyl chloride, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 357424-25-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 357424-47-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 357425-94-6 CAPLUS
CN Ethanethioamide, N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoro-1-thioethyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 357425-98-0 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357425-99-1 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-86-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)




RN 328055-99-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-20-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-b][3]benzazepine, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)




L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357426-00-7 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-01-8 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-02-9 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-04-1 CAPLUS
CN Propanamide, 3,3-dimethoxy-N-[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357426-05-2 CAPLUS
CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-06-3 CAPLUS
CN 6,10-Methano-8H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-07-4 CAPLUS
CN 6,10-Methano-8H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid, 2-chloro-6,7,9,10-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 357426-08-5 CAPLUS
CN 6,10-Methano-8H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid, 1,5-Methano-1H-3-benzazepine-7-amine, 2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-3-yl)-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 474024-48-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-3-yl)-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 474024-59-4 CAPLUS
CN 6,10-Methano-8H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid, 6,7,9,10-tetrahydro-2,3-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 230615-05-1P 230615-06-2P 230615-07-3P
230615-09-5P 230615-10-8P 230615-11-9P
230615-12-0P 230615-13-1P 230615-14-2P
230615-15-3P 230615-16-4P 230615-17-5P
230615-18-6P 230615-19-7P 230615-20-0P
230615-21-1P 230615-22-2P 230615-23-3P
230615-24-4P 230615-25-5P 230615-26-6P
230615-27-7P 230615-28-8P 230615-29-9P
230615-30-2P 230615-31-3P 230615-32-4P
230615-33-5P 230615-34-6P 230615-35-7P
230615-36-8P 230615-37-9P 230615-38-0P
230615-39-1P 230615-40-4P 357425-82-2P
357425-83-3P 357425-86-6P 357425-87-7P
357425-88-8P 357425-89-9P 357425-90-2P
357425-92-4P 357425-93-5P 357426-13-2P
474024-49-2P 474024-50-5P 474024-51-6P
474024-52-7P 474024-58-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 1,3-substituted indenes as intermediates for aryl-fused azapolycyclic compds. with cholinergic function)


RN 230615-05-1 CAPLUS

Page 26


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357426-10-9 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-21-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-[3-(dimethylamino)-1-oxo-2-propenyl]-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 474024-46-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-3-carboxylic acid, 7-amino-1,2,4,5-tetrahydro-8-[(2-methylpropyl)amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 474024-47-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-5-yl)-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-06-2 CAPLUS
CN Acetamide, N-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-07-3 CAPLUS
CN 5,9-Methano-5H-thiazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-09-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-10-8 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-11-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-12-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-16-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-17-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-18-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-13-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-14-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-15-3 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-19-7 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-20-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-1,5,6,7,8,9-hexahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-21-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-22-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-, 1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-23-3 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-24-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-28-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-29-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-30-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-25-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-26-6 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-27-7 CAPLUS
CN Benzamide, 2-fluoro-N-(2,3,4,5-tetrahydro-8-hydroxy-1,5-methano-1H-3-benzazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl

RN 230615-31-3 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-32-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-33-5 CAPLUS
CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-34-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-5-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-35-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-5-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-36-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-40-4 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepine-2-one, 3,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 357425-82-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 357425-83-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-37-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-38-0 CAPLUS
CN Pyrrolidine, 1-[(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-39-1 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepine-2(1H)-one, 3,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)


L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 357425-86-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 357425-87-7 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 357425-88-8 CAPLUS
CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepine-2-one, 1,6,7,8,9,10-hexahydro-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 357425-89-9 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 357425-90-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-b][3]benzazepine, 7,8,9,10-tetrahydro-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 357425-92-4 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-b][3]benzazepine-2-one, 1,6,7,8,9,10-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 357425-93-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 69718-72-5
CMF C11 H13 N

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 474024-51-6 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-(1-methyl-ethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 474024-52-7 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-b][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 474024-58-3 CAPLUS
CN 5,9-Methano-5H-thiazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-7-(2,2,2-trifluoro-1-thioethyl)- (9CI) (CA INDEX NAME)




L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




CM 2


CRN 104-15-4
CMF C7 H8 O3 S



RN 357426-13-2 CAPLUS
CN 1,5-Methano-2H-3-benzazepine-2-one, 1,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 474024-49-2 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-(1-methyl-ethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 474024-50-5 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepine, 2-ethyl-3,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:695763 CAPLUS
DOCUMENT NUMBER: 137:210972
TITLE: Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders
INVENTOR(S): Villalobos, Anabella
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069948	A1	20020912	WO 2002-18515	20020220
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PA, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW:	GE, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1363606	A1	20031126	EP 2002-700509	20020220
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
EE 200300422	A	20040216	EE 2003-422	20020220
BR 2002007802	A	20040309	BR 2002-7802	20020220
US 2002193360	A1	20021219	US 2002-83743	20020226
NO 2003003821	A	20030910	NO 2003-3821	20030828
US 2004082555	A1	20040429	US 2003-727934	20031202
PRIORITY APPLN. INFO.:			US 2001-272566P	20010301
			WO 2002-18515	W 20020220
			US 2002-83743	A1 20020226

OTHER SOURCE(S): MARPAT 137:210972
AB A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal comprising administration of a GABAA inverse agonist or a pharmaceutically acceptable salt thereof; and a nicotine receptor partial agonist, an estrogenic agent, selective estrogen receptor modulator or vitamin E or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The GABAA inverse agonist, and nicotine receptor partial agonist, estrogen, selective estrogen receptor modulator or vitamin E are present in amounts that render the composition effective enhancing cognition or in the treatment of diseases of cognitive dysfunction including but not limited to Alzheimer's Disease (AD), mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease, Huntington's disease, memory impairment associated with depression or anxiety, schizophrenia, Down's syndrome, stroke, traumatic brain injury (TBI), AIDS associated dementia and attention deficit disorder. The method of using these compounds is also disclosed.
IT 69718-72-5 249296-44-4 207973-26-6
287973-27-7 328055-77-2 328055-78-3
328055-79-4 328055-80-7 328055-81-8
328055-84-1 328055-85-2 328055-86-3

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

328055-87-4 328055-88-5 328055-89-6
328055-90-9 328055-92-1 328055-94-3
328055-95-4 328055-96-5 328055-97-6
328055-99-8 328056-66-2 357424-19-2
367511-27-1 367511-30-6 367511-30-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(use of GABA inverse agonists in combination with nicotine receptor
partial agonists or estrogen or selective estrogen modulators or
vitamin E for treatment of cognitive disorders)


RN 69718-72-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI)
(CA INDEX NAME)



RN 287973-26-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA
INDEX NAME)




RN 287973-27-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-ethynyl-2,3,4,5-tetrahydro-
(9CI) (CA INDEX NAME)




RN 328055-77-2 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-

L22 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-84-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl- (9CI) (CA
INDEX NAME)




RN 328055-85-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)-
(9CI) (CA INDEX NAME)



RN 328055-86-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX
NAME)



RN 328055-87-4 CAPLUS
CN 5,9-Methanimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-
(9CI) (CA INDEX NAME)




RN 328055-88-5 CAPLUS
CN 5,9-Methanimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-
(9CI) (CA INDEX NAME)


Page 31

L22 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


methyl- (9CI) (CA INDEX NAME)




RN 328055-78-3 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-
(9CI) (CA INDEX NAME)



RN 328055-79-4 CAPLUS
CN 5,9-Methanimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-
(9CI) (CA INDEX NAME)




RN 328055-80-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro- (9CI) (CA
INDEX NAME)




RN 328055-81-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro- (9CI)
(CA INDEX NAME)


L22 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-89-6 CAPLUS
CN 5,9-Methanimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-
dimethyl- (9CI) (CA INDEX NAME)




RN 328055-90-9 CAPLUS
CN 5,9-Methanimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-
phenyl- (9CI) (CA INDEX NAME)



RN 328055-92-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-
methyl- (9CI) (CA INDEX NAME)



RN 328055-94-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA
INDEX NAME)




RN 328055-95-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI)
(CA INDEX NAME)

Page 31

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-96-5 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 328055-97-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-99-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328056-66-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-19-2 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h] [3]benzazepine, 7,8,9,10-tetrahydro-2,3-


L22 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
dimethyl- (9CI) (CA INDEX NAME)




RN 367511-27-1 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h] [3]benzazepin-3(5H)-one, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 367511-30-6 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h] [3]benzazepin-3(5H)-one, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 367511-38-4 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h] [3]benzazepin-1(5H)-one, 6,7,8,9-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:671909 CAPLUS
DOCUMENT NUMBER: 137:201144
TITLE: Sulfamide derivatives useful as β_3 agonists
INVENTOR(S): Dow, Robert Lee; Paight, Ernest Sidney, Jr.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 41 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1236723	A1	20020904	EP 2002-251221	20020222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2002326983	A2	20021115	JP 2002-51109	20020227
US 2002128247	A1	20020912	US 2002-86588	20020228
BR 2002000626	A	20030715	BR 2002-626	20020301
PRIORITY APPLN. INFO.:			US 2001-272681 P 20010301	
OTHER SOURCE(S):			MARPAT 137:201144	
G1				



I



II

AB Sulfamides ROCHArCH2NR1CR2R3CH2XC6H4NR5SO2NR6R7 [Ar = (un)substituted aryl, heteroaryl; R = H, protective group; R1 = H, alkyl, protective group; RR1 = bond; R2, R3, R5 = H, alkyl; R6, R7 = h, (un)substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl; NR6R7 = cyclic amino; X = bond, O, S, S(O), SO2, (un)substituted NH in which the benzene ring may be further substituted by halogen, CN, (un)substituted alkyl, alkoxy] were prepared for use in the treatment of diseases dependent on the signaling pathways associated with β -adrenergic receptors, such as obesity, diabetes, hypertension, gastrointestinal hypo- or hyper-motility and cardiovascular diseases. Thus, 4-O2NC6H4CH2CMe2NH2 was treated with (R)-3-chlorostyrene oxide, cyclized to the nitrophenyloxazolidinone, the nitro group reduced to amine, and treated with 1-piperidinesulfamoyl chloride to give the oxazolidine I which was treated with KOH to give the title compound II. All the products showed selective β_3 -adrenergic activity.


IT 454218-95-2P 454219-69-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L22 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of sulfamides with selective β_3 agonist activity)

RN 454218-95-2 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-sulfonamide, 1,2,4,5-tetrahydro-N-[4-[2-[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-7-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HC1

RN 454219-69-3 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-sulfonamide, 1,2,4,5-tetrahydro-N-[4-[2-[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Aryl Fused Azapolycyclic Compounds

L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:104621 CAPLUS

DOCUMENT NUMBER: 136:145265

TITLE: A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) comprising a nicotine receptor partial agonist and anti-ADHD agent

INVENTOR(S): Watsky, Eric Jacob; Coe, Jotham Wadsworth; Harrigan, Edmund Patrick; O'Neill, Brian Thomas; Sands, Steven Bradley

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 19 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1177798	A2	20020206	EP 2001-306455	20010727
EP 1177798	A3	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002016334	A1	20020207	US 2001-865793	20010525
BR 2001003169	A	20020528	BR 2001-3169	20010731
JP 2002316949	A2	20021031	JP 2001-231554	20010731
PRIORITY APPLN. INFO.: US 2000-221718P P 20000731				
AB Pharmaceutical compns. are disclosed for the treatment of attention deficit hyperactivity disorder (ADHD). The pharmaceutical compns. are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an anti-ADHD agent and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.				
IT 69718-72-5 69718-72-5D, isomers 69718-77-0 69718-77-0D, isomers 230615-75-5 230615-75-5D, isomers 249296-44-4 249296-44-4D, isomers 287973-26-6 287973-26-6D, isomers 287973-27-7 287973-27-7D, isomers 328055-77-2 328055-77-2D, isomers 328055-78-3 328055-78-3D, isomers 328055-79-4 328055-79-4D, isomers 328055-80-7 328055-80-7D, isomers 328055-81-8 328055-81-8D, isomers 328055-83-0 328055-83-0D, isomers 328055-85-2 328055-85-2D, isomers 328055-86-3 328055-86-3D, isomers 328055-87-4 328055-87-4D, isomers 328055-88-5 328055-88-5D, isomers 328055-89-6 328055-89-6D, isomers 328055-90-9 328055-90-9D, isomers 328055-92-1 328055-92-1D, isomers 328055-94-3 328055-94-3D, isomers 328055-95-4 328055-95-4D, isomers 328055-96-5 328055-96-5D, isomers 328055-97-6 328055-97-6D, isomers 328055-98-7 328055-98-7D, isomers 328055-99-8 328055-99-8D, isomers 328056-66-2 328056-66-2D, isomers 357424-19-2 357424-19-2D, isomers 357424-20-5 357424-20-5D, isomers				
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				

L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

(nicotine receptor partial agonist and anti-attention deficit hyperactivity disorder agent for pharmaceutical compn. for treatment of attention deficit hyperactivity disorder)

RN 69718-72-5 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 69718-72-5 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 69718-77-0 CAPLUS

CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)



RN 69718-77-0 CAPLUS


CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)



RN 230615-75-5 CAPLUS


CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)

L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 230615-75-5 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 249296-44-4 CAPLUS

CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 249296-44-4 CAPLUS

CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 287973-26-6 CAPLUS


CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 287973-26-6 CAPLUS


CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)

L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 287973-27-7 CAPLUS

CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-ethynyl-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 287973-27-7 CAPLUS

CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-ethynyl-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-77-2 CAPLUS

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 328055-77-2 CAPLUS

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 328055-78-3 CAPLUS


CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-78-3 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



RN 328055-79-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-79-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-80-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-80-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-81-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-81-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-83-0 CAPLUS
CN 5,9-Methano-2H-isothiazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 328055-83-0 CAPLUS
CN 5,9-Methano-2H-isothiazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-


L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-85-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 328055-85-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 328055-86-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)




RN 328055-86-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)




RN 328055-87-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-87-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)




RN 328055-88-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 328055-88-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 328055-89-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)




Aryl Fused Azapolycyclic Compounds


L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 328055-89-6 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)



RN 328055-90-9 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)



RN 328055-90-9 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)




RN 328055-92-1 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)




RN 328055-92-1 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 (CA INDEX NAME)



RN 328055-96-5 CAPLUS
 CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 328055-97-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-97-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-98-7 CAPLUS
 CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)




RN 328055-98-7 CAPLUS


L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-94-3 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-94-3 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-95-4 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-95-4 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-96-5 CAPLUS
 CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI)


L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)



RN 328055-99-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-99-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328056-66-2 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328056-66-2 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




Aryl Fused Azapolycyclic Compounds


L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 357424-19-2 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)




RN 357424-19-2 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 357424-20-5 CAPLUS
 CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-20-5 CAPLUS
 CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)



L22 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 (comps. comprising nicotine receptor partial agonist and antiobesity agent for treatment of obesity and related disorders)
 RN 69718-72-5 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 230615-75-5 CAPLUS
 CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 249296-44-4 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 287973-26-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 287973-27-7 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-ethynyl-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-77-2 CAPLUS
 CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-

L22 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:885334 CAPLUS
 DOCUMENT NUMBER: 136:658
 TITLE: A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss, comprising a nicotine receptor partial agonist and an anti-obesity agent
 INVENTOR(S): Coe, Jotham W.; O'Neill, Brian T.; Sands, Steven B.; Dow, Robert L. B.; Harrigan, Edmund P.; Watsky, Eric J.
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 16 pp.
 CODEN: EPXRXW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1159970	A2	20011205	EP 2001-304806	20010531
EP 1159970	A3	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002010192	A1	20020124	US 2001-850042	20010507
BR 2001002211	A	20020305	BR 2001-2211	20010530
JP 2002012558	A2	20020115	JP 2001-164010	20010531
US 2003176457	A1	20030918	US 2003-366532	20030213
PRIORITY APPLN. INFO.:			US 2000-208856P	P 20000602
			US 2001-850042	B1 20010507

AB Pharmaceutical comps. are disclosed for the treatment of obesity, an overweight condition and compulsive overeating. The pharmaceutical comps. are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an anti-obesity agent or weight loss facilitator or promoter, such as Xenical and Meridia, and a pharmaceutically acceptable carrier. The nicotine receptor partial agonist and an anti-obesity agent or weight loss facilitator are administered substantially simultaneously. A method of treating a disorder or condition in which obesity or an overweight condition predominates, including type 2 diabetes mellitus, hypertension, dyslipidemia, and increased mortality in a mammal comprises administering a composition containing nicotine receptor partial agonist and an anti-obesity agent.
 IT 69718-72-5 230615-75-5 249296-44-4
 287973-26-6 287973-27-7 328055-77-2
 328055-78-3 328055-79-4 328055-80-7
 328055-81-8 328055-83-0 328055-84-1
 328055-85-2 328055-86-3 328055-87-4
 328055-88-5 328055-89-6 328055-90-9
 328055-92-1 328055-94-3 328055-95-4
 328055-96-5 328055-97-6 328055-98-7
 328055-99-8 328055-66-2 357424-19-2
 357424-20-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


L22 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 methyl- (9CI) (CA INDEX NAME)




RN 328055-78-3 CAPLUS
 CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-79-4 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



RN 328055-80-7 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-81-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-83-0 CAPLUS
 CN 5,9-Methano-2H-isothiazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 328055-84-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



RN 328055-85-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 328055-86-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)




RN 328055-87-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-94-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-95-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-96-5 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 328055-97-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-98-7 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-88-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 328055-89-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)




RN 328055-90-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)




RN 328055-92-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-99-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328056-66-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 357424-19-2 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 357424-20-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)



Aryl Fused Azapolycyclic Compounds

L22 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:964711 CAPLUS
 DOCUMENT NUMBER: 13611124
 TITLE: Reactive crystallization method to improve particle size
 INVENTOR(S): Am Ende, David Jon; Crawford, Thomas Charles; Weston, Neil Philip
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 11 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1157726	A1	20011128	EP 2001-304422	20010518
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BG 105518	A	20011231	BG 2001-105518	20010517
JP 2002028475	A2	20020129	JP 2001-153592	20010523
US 2002016498	A1	20020207	US 2001-863492	20010523
US 6558435	B2	20030506		
ZA 2001004207	A	20021125	ZA 2001-4207	20010523
TR 200101453	A2	20011221	TR 2001-200101453	20010524
HR 2001000399	A1	20021231	HR 2001-399	20010524
NO 2001002571	A	20011127	NO 2001-2571	20010525
CN 1326803	A	20011219	CN 2001-119055	20010525
EE 200100284	A	20020215	EE 2001-284	20010525
BR 2001002129	A	20020521	BR 2001-2129	20010525
NZ 511966	A	20021126	NZ 2001-511966	20010525
SG 96223	A1	20030523	SG 2001-3136	20010525

PRIORITY APPLN. INFO.: US 2000-207629P P 20000526
 AB This invention provides a method of conducting a simultaneous chemical reaction and controlled crystallization of the product employing impinging fluid jet streams containing reactants capable of producing the product with desired particle size characteristics. An example is give for reaction and crystallization of ziprasidone to achieve the desired ziprasidone-HCl.H₂O.
 IT 249296-44-4
 RL: FRP (Properties); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
 (reactive crystallization method to improve particle size)
 RN 249296-44-4 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




L22 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:798756 CAPLUS
 DOCUMENT NUMBER: 135:339282
 TITLE: Nicotine receptor partial agonist, cholinesterase inhibitor, and estrogenic agent composition for treatment of diseases of cognitive dysfunction in a mammal
 INVENTOR(S): Coe, Jotham Wadsworth; Sands, Steven Bradley; Harrigan, Edmund Patrick; O'Neill, Brian Thomas; Watsky, Eric Jacob
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 20 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001036949	A1	20011101	US 2001-760966	20010116
WO 2001085145	A2	20011115	WO 2001-1B681	20010424
WO 2001085145	A3	20020613		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1280554	A2	20030205	EP 2001-921733	20010424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001010487	A	20030401	BR 2001-10487	20010424
JP 2003532670	T2	20031105	JP 2001-581799	20010424
US 2003130303	A1	20030710	US 2003-347955	20030121


PRIORITY APPLN. INFO.: US 2000-202798P P 20000509
 US 2001-760966 B1 20010116
 WO 2001-1B681 W 20010424
 AB A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal comprising administration of a nicotine receptor partial agonist or a pharmaceutically acceptable salt thereof; and an acetylcholinesterase inhibitor, butyrylcholinesterase inhibitor, an estrogenic agent, selective estrogen receptor modulator or muscarinic agonist or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The nicotine receptor partial agonist and acetylcholinesterase inhibitor, butyrylcholinesterase inhibitor, estrogen, selective estrogen receptor modulator or muscarinic agonist are present in amts. that render the composition effective enhancing cognition
 or
 in the treatment of diseases of cognitive dysfunction including but not limited to Alzheimer's Disease, mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease dementia, Huntington's Disease, Stroke, TBI, AIDS associated dementia and schizophrenia. The method of using these compns. is also disclosed.
 IT 69718-72-5 230615-75-5 249296-44-4
 287973-26-6 287973-27-7 328055-77-2

L22 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 IT 375815-87-5P
 RL: FRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (reactive crystallization method to improve particle size)
 RN 375815-87-5 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)
 CH 1
 CRN 249296-44-4
 CHF C13 H13 N3



CH 2
 CRN 87-69-4
 CHF C4 H6 O6

Absolute stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L22 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 328055-78-3 328055-79-4 328055-80-7
 328055-81-8 328055-83-0 328055-84-1
 328055-85-2 328055-86-3 328055-87-4
 328055-88-5 328055-89-6 328055-90-9
 328055-92-1 328055-94-3 328055-95-4
 328055-96-5 328055-97-6 328055-98-7
 328055-99-8 328055-66-2 357424-19-2
 357424-20-5
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nicotine receptor partial agonist, cholinesterase inhibitor, and estrogenic agent compn. for treatment of diseases of cognitive dysfunction in a mammal)
 RN 69718-72-5 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 230615-75-5 CAPLUS
 CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 249296-44-4 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 287973-26-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 287973-27-7 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-ethynyl-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-77-2 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 328055-78-3 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-79-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-80-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




L22 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-87-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)




RN 328055-88-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 328055-89-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)




RN 328055-90-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)




RN 328055-92-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-b][3]benzazepine, 7,8,9,10-tetrahydro-8-

L22 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 328055-81-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-83-0 CAPLUS
CN 5,9-Methano-2H-isothiazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 328055-84-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



RN 328055-85-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 328055-86-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)

L22 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-94-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-95-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-96-5 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 328055-97-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-98-7 CAPLUS
CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-99-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328056-66-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 357424-19-2 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 357424-20-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)



L22 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 20011762800 CAPLUS
DOCUMENT NUMBER:
TITLE: A pharmaceutical composition containing a nicotine receptor agonist and an analgesic for treatment of acute, chronic pain and/or neuropathic pain and migraines
INVENTOR(S): Coe, Jotham Wadsworth; Harrigan, Edmund Patrick; O'Neill, Brian Thomas; Sands, Steven Bradley; Watsky, Eric Jacob
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 41 pp.
DOCUMENT TYPE: CODEN: PIXX02
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: English
PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001076576	A2	20011018	WO 2001-1B391	20010316
WO 2001076576	A3	20020620		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2001036943	A1	20011101	US 2000-740307	20001218
EP 1272218	A2	20030108	EP 2001-910097	20010316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009837	A	20030121	BR 2001-9837	20010316
JP 2003530345	T2	20031014	JP 2001-574094	20010316
BG 107138	A	20030530	BG 2002-107138	20020923
US 2003133951	A1	20030717	US 2003-348381	20030121
PRIORITY APPLN. INFO.: US 2000-1957382 P 20000407 US 2000-740307 B1 20001218 WO 2001-1B391 W 20010316				

AB Oral, parenteral or transdermal compns. are disclosed for the treatment of acute, chronic and/or neuropathic pain. The pharmaceutical compns. are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an analgesic agent and a pharmaceutically acceptable carrier. The analgesic agent is selected from opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants, migraine therapeutic agents, anticonvulsants, antihypertensives, antiarrhythmics, antihistamines, steroids, caffeine, N-type calcium channel antagonists and botulinum toxin. The method of using these compns. and a method of treating acute, chronic and/or neuropathic pain and migraine in a mammal including a human is also disclosed.
IT 69718-72-5 249296-44-4 287973-26-6
287973-27-7 328055-77-2 328055-78-3
328055-79-4 328055-80-7 328055-81-8
328055-83-0 328055-84-1 328055-85-2


L22 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

L22 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


328055-86-3 328055-87-4 328055-88-5
328055-89-6 328055-90-9 328055-92-1
328055-94-3 328055-95-4 328055-96-5
328055-97-6 328055-99-8 328056-66-2
357424-19-2 367511-27-1 367511-30-6
367511-38-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. contg. nicotine receptor agonist and analgesic for treatment of acute, chronic pain and/or neuropathic pain and migraines)
RN 69718-72-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 287973-26-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 287973-27-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-ethynyl-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-77-2 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 328055-78-3 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-79-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



RN 328055-80-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-81-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-83-0 CAPLUS


L22 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-88-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 328055-89-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)



RN 328055-90-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)




RN 328055-92-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-b][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)




RN 328055-94-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 5,9-Methano-2H-isothiazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 328055-84-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



RN 328055-85-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 328055-86-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)



RN 328055-87-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-95-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-96-5 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 328055-97-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-99-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328056-66-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-19-2 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 367511-27-1 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-3(5H)-one, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 367511-30-6 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-3(5H)-one, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 367511-38-4 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(5H)-one, 6,7,8,9-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:636053 CAPLUS
DOCUMENT NUMBER: 135:210949
TITLE: Preparation of aryl-fused azapolycyclic compounds as nicotine binding inhibitors
INVENTOR(S): Brooks, Paige Roanne Palmer; Coe, Jotham Wadsworth
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: FCT Int. Appl., 110 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062736	A1	20010830	WO 2001-1B153	20010208
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6605610	B1	20030812	US 2000-514002	20000225
BR 2001008610	A	20021119	BR 2001-8610	20010208
EP 1259489	A1	20021127	EP 2001-953630	20010208
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, UT, LV, FI, RO, MK, CY, AL, TR			
JP 2003524002	T2	20030812	JP 2001-562518	20010208
EE 200200475	A	20031215	EE 2002-475	20010208
BG 106908	A	20030430	BG 2002-106908	20020705
NO 2002004042	A	20021017	NO 2002-4042	20020823
PRIORITY APPLN. INFO.:			US 2000-514002	A 20000225
			US 1997-70245P	P 19971231
			WO 1998-151813	A2 19981113
			US 1999-402010	A2 19990928
			WO 2001-1B153	W 20010208


OTHER SOURCE(S): MARPAT 135:210949
GI



AB The invention discloses the preparation of aryl-fused azapolycyclic compds., such as I (R1 = H, alkyl, unconjugated alkenyl, benzyl, X(CO)R13, CH2CH2O-alkyl; R2, R3 = H, alkenyl, alkynyl, hydroxy, nitro, amino, halo, cyano, SOalkyl, (q = 0 - 2), alkylamino, CO2R4, CONR5R6, SO2NR7R8, COR13, X(CO)R13; R2 and R3, together with the carbons to which they are attached

Page 42

L22 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

form a 4-7 membered monocyclic ring or a 10-14 membered bicyclic ring; R4-R8, R13 = H, alkyl or R5 and R6, or R7 and R8 together with nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, thiomorpholine; X = alkylene), and their pharmaceutically acceptable salts, as nicotine binding inhibitors (IC50 < 10 μ M) in the treatment of neurol. and psychol. disorders. Thus, aryl-fused azapolycyclic compd. I (R1-R3 = H) was prepd. via a multistep synthetic sequence starting from 2-fluorobromobenzene via a cycloaddn. with cyclopentadiene and an amination with triethylbenzylammonium chloride.


IT 230615-08-4P 328055-86-3P 328055-99-8P
357424-19-2P 357424-20-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aryl-fused azapolycyclic compds. as nicotine binding inhibitors)


RN 230615-08-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7,8-dinitro- (9CI) (CA INDEX NAME)



RN 328055-86-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)




RN 328055-99-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-19-2 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 357424-20-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro- (9CI)
(CA INDEX NAME)



IT 69718-72-5P 230614-99-0P 230615-00-6P
230615-01-7P 230615-02-8P 230615-03-9P
230615-04-0P 230615-05-1P 230615-06-2P
230615-07-3P 230615-09-5P 230615-10-8P
230615-11-9P 230615-12-0P 230615-13-1P
230615-14-2P 230615-15-3P 230615-16-4P
230615-17-5P 230615-18-6P 230615-19-7P
230615-20-0P 230615-21-1P 230615-22-2P
230615-23-3P 230615-24-4P 230615-25-5P
230615-26-6P 230615-27-7P 230615-28-8P
230615-29-9P 230615-30-2P 230615-31-3P
230615-32-4P 230615-33-5P 230615-34-6P
230615-35-7P 230615-36-8P 230615-37-9P
230615-38-0P 230615-39-1P 230615-40-4P
230615-41-5P 230615-42-6P 230615-43-7P
230615-44-8P 230615-45-9P 230615-46-0P
230615-75-5P 249296-44-4P 287973-24-4P
287973-25-5P 287973-26-6P 287973-27-7P
287973-28-8P 287973-29-9P 287973-32-4P
328055-77-2P 328055-78-3P 328055-79-4P
328055-80-7P 328055-81-8P 328055-84-1P
328055-85-2P 328055-87-4P 328055-88-5P
328055-89-6P 328055-90-9P 328055-92-1P
328055-94-3P 328055-95-4P 328055-96-5P
328055-97-6P 328055-98-7P 328056-66-2P
357424-02-3P 357424-03-4P 357424-04-5P
357424-05-6P 357424-06-7P 357424-07-8P
357424-08-9P 357424-09-0P 357424-10-3P
357424-11-4P 357424-12-5P 357424-13-6P
357424-14-7P 357424-15-8P 357424-16-9P
357424-17-0P 357424-18-1P 357424-21-6P
357424-22-7P 357424-23-8P 357424-24-9P
357424-25-0P 357424-26-1P 357424-27-2P
357424-28-3P 357424-29-4P 357424-30-7P
357424-31-8P 357424-32-9P 357424-34-1P
357424-36-3P 357424-37-4P 357424-39-6P

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


357424-41-0P 357424-43-2P 357424-45-4P
357424-47-6P 357424-49-8P 357424-51-2P
357424-53-4P 357424-55-6P 357424-57-8P
357424-59-0P 357424-61-4P 357424-62-5P
357424-63-6P 357424-64-7P 357424-65-8P
357424-66-9P 357424-67-0P 357424-68-1P
357424-69-2P 357424-70-5P 357424-71-6P
357424-72-7P 357424-73-8P 357424-74-9P
357424-75-0P 357424-76-1P 357424-77-2P
357424-78-3P 357424-79-4P 357424-80-7P
357424-81-8P 357424-82-9P 357424-83-0P
357424-84-1P 357424-85-2P 357424-86-3P
357424-87-4P 357424-88-5P 357424-89-6P
357424-90-9P 357424-91-0P 357424-92-1P
357424-93-2P 357424-94-3P 357424-95-4P
357424-96-5P 357424-97-6P 357424-98-7P
357424-99-8P 357425-00-4P 357425-02-6P
357425-03-7P 357425-04-8P 357425-05-9P
357425-07-1P 357425-09-3P 357425-10-6P
357425-12-8P 357425-13-9P 357425-15-1P
357425-17-3P 357425-18-4P 357425-20-8P
357425-22-0P 357425-24-2P 357425-26-4P
357425-27-5P 357425-28-6P 357425-29-7P
357425-30-0P 357425-31-1P 357425-32-2P
357425-33-3P 357425-34-4P 357425-35-5P
357425-36-6P 357425-37-7P 357425-38-8P
357425-39-9P 357425-40-2P 357425-41-3P
357425-42-4P 357425-43-5P 357425-44-6P
357425-45-7P 357425-46-8P 357425-47-9P
357425-48-0P 357425-49-1P 357425-50-4P
357425-51-5P 357425-52-6P 357425-53-7P
357425-54-8P 357425-55-9P 357425-56-0P
357425-57-1P 357425-58-2P 357425-59-3P
357425-60-6P 357425-61-7P 357425-62-8P
357425-63-9P 357425-64-0P 357425-65-1P
357425-66-2P 357425-67-3P 357425-68-4P
357425-69-5P 357425-70-8P 357425-71-9P
357425-72-0P 357425-73-1P 357425-74-2P
357425-75-3P 357425-76-4P 357425-77-5P
357425-78-6P 357425-79-7P 357425-80-0P
357425-81-1P 357425-82-2P 357425-83-3P
357425-84-4P 357425-86-6P 357425-87-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl-fused azapolycyclic compds. as nicotine binding inhibitors)

RN 69718-72-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230614-99-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-00-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-01-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-02-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-03-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 6-fluoro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-04-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-05-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-amine, 2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-06-2 CAPLUS
CN Acetamide, N-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-07-3 CAPLUS
CN 5,9-Methano-5H-thiazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-09-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-13-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-14-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-15-3 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-10-8 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-11-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-12-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-16-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-17-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-18-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-19-7 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-20-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-21-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-22-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-23-3 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-24-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-25-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-26-6 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-27-7 CAPLUS
CN Benzamide, 2-fluoro-N-(2,3,4,5-tetrahydro-8-hydroxy-1,5-methano-1H-3-benzazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-28-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-29-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-30-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-31-3 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-32-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-ol, 2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-33-5 CAPLUS
CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-37-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-38-0 CAPLUS
CN Pyrrolidine, 1-[(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-39-1 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-34-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-5-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-35-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-36-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl

RN 230615-40-4 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-41-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-42-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-6-ol, 2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-43-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-44-8 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 2-ethyl-6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-45-9 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-46-0 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-(phenylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-75-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 287973-24-4 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepine-1,3(2H,5H)-dione, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 287973-25-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-2(1H)-one, 3,5,6,7,8,9-hexahydro-1,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 287973-26-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



RN 287973-27-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-ethynyl-2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



RN 287973-28-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 287973-29-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-8-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 287973-32-4 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepine-1,3(2H,5H)-dione, 5,6,7,8-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 328055-77-2 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepine-1,3(2H,5H)-dione, 3,5,6,7,8,9-hexahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 328055-78-3 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepine-1,3(2H,5H)-dione, 3,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 328055-79-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-2(1H)-one, 3,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 328055-80-7 CAPLUS

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-81-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-84-1 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



RN 328055-85-2 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 328055-87-4 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-94-3 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-95-4 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-96-5 CAPLUS
 CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 328055-97-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-98-7 CAPLUS
 CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-88-5 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 328055-89-6 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)




RN 328055-90-9 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)




RN 328055-92-1 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328056-66-2 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-02-3 CAPLUS
 CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



RN 357424-03-4 CAPLUS
 CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 357424-04-5 CAPLUS
 CN Benzamide, 2-fluoro-N-(2,3,4,5-tetrahydro-8-hydroxy-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 357424-05-6 CAPLUS
 CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-06-7 CAPLUS
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepin-3-amine, 6,7,8,9-tetrahydro-N,N-dimethyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 357424-07-8 CAPLUS
CN 6,10-Methano-1H-pyrazino[2,3-h][3]benzazepine-2,3-dione, 4,6,7,8,9,10-hexahydro- (9CI) (CA INDEX NAME)




RN 357424-08-9 CAPLUS
CN 6,10-Methano-1H-pyrazino[2,3-h][3]benzazepine-2,3-dione, 4,6,7,8,9,10-hexahydro-1,4-dimethyl- (9CI) (CA INDEX NAME)




RN 357424-09-0 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-3-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-14-7 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



RN 357424-15-8 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2-methylpropyl)-1,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 357424-16-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-phenyl-1,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 357424-17-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-1,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-10-3 CAPLUS
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 357424-11-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-propyl- (9CI) (CA INDEX NAME)




RN 357424-12-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 357424-13-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-18-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 357424-21-6 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro- (9CI) (CA INDEX NAME)



RN 357424-22-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-amine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-23-8 CAPLUS
CN Acetamide, N-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 357424-24-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-25-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 357424-26-1 CAPLUS
CN Pyrrolidine, 1-[(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 357424-27-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-28-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-8-ethynyl-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-36-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-37-4 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 357424-39-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)



RN 357424-41-0 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-43-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl- (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 357424-29-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 357424-30-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-2,3,4,5-tetrahydro-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 357424-31-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7,8-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 357424-32-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 357424-34-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 6-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-45-4 CAPLUS
CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro- (9CI) (CA INDEX NAME)




RN 357424-47-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 357424-49-8 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methoxy- (9CI) (CA INDEX NAME)




RN 357424-51-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-5-fluoro-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 357424-53-4 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-11-fluoro-7,8,9,10-


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-55-6 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-57-8 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-59-0 CAPLUS
CN Benzamide, 2-fluoro-N-(2,3,4,5-tetrahydro-8-hydroxy-1,5-methano-1H-3-benzazepin-7-yl)-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-61-4 CAPLUS

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-65-8 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-3-methyl-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-66-9 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).



RN 357424-67-0 CAPLUS
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-68-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-propyl-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-62-5 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).



RN 357424-63-6 CAPLUS
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, 1,1-dioxide, (+)-(9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-64-7 CAPLUS
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-N,N-dimethyl-, 1,1-dioxide, (+)-(9CI) (CA INDEX NAME)


Rotation (+).

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-69-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-70-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).



RN 357424-71-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl-, (+)-(9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-72-7 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro-, (+)-(9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Rotation (+).




RN 357424-73-8 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2-methylpropyl)-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-74-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-75-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-phenyl-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-76-1 CAPLUS

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-80-7 CAPLUS
CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-81-8 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepine-2-one, 1,6,7,8,9,10-hexahydro-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).



RN 357424-82-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-83-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-, 1,5,6,7,8,9-hexahydro-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-77-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-, 1,5,6,7,8,9-hexahydro-2-methyl-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).



RN 357424-78-3 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-, (+)-(9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-79-4 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, (+)-(9CI) (CA INDEX NAME)


Rotation (+).

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-84-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-amine, 2,3,4,5-tetrahydro-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-85-2 CAPLUS
CN Acetamide, N-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).



RN 357424-86-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-87-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-88-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-ol, 2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-89-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357424-90-9 CAPLUS
CN Pyrrolidine, 1-[(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepine-7-yl)sulfonyl]-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-91-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-92-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-ethynyl-2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-93-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-ethynyl-2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357424-94-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-chloro-2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-95-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357424-96-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-fluoro-2,3,4,5-tetrahydro-8-(trifluoromethyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-97-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-chloro-2,3,4,5-tetrahydro-8-(trifluoromethyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-98-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-8-(trifluoromethyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357424-99-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-ethynyl-2,3,4,5-tetrahydro-8-(trifluoromethyl)-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 357425-00-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-2,3,4,5-tetrahydro-6-(trifluoromethyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357425-02-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-2,3,4,5-tetrahydro-7-(trifluoromethyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357425-03-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-6-fluoro-2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357425-04-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357425-05-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-fluoro-2,3,4,5-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(CA INDEX NAME)

Rotation (+).




RN 357425-07-1 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357425-09-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357425-10-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357425-12-8 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-20-8 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-5-fluoro-7,8,9,10-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357425-22-0 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-11-fluoro-7,8,9,10-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357425-24-2 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-26-4 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-13-9 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357425-15-1 CAPLUS
CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 357425-17-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357425-18-4 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methoxy-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-27-5 CAPLUS
CN Benzamide, 2-fluoro-N-(2,3,4,5-tetrahydro-8-hydroxy-1,5-methano-1H-3-benzazepin-7-yl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-28-6 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-29-7 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-30-0 CAPLUS
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, 1,1-dioxide, (-)- (9CI) (CA INDEX NAME)

Rotation (-).


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-31-1 CAPLUS
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepin-3-amine, 6,7,8,9-tetrahydro-N,N-dimethyl-, 1,1-dioxide, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-32-2 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-3-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-33-3 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-34-4 CAPLUS
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, (-)- (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 357425-38-8 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-39-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-40-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-(2-methylpropyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-41-3 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-phenyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Rotation (-).




RN 357425-35-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-propyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-36-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-37-7 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 357425-42-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-43-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-, 1,5,6,7,8,9-hexahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-44-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-, 1,5,6,7,8,9-hexahydro-2-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-45-7 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



Aryl Fused Azapolycyclic Compounds


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 357425-46-8 CAPLUS
 CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-47-9 CAPLUS
 CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-48-0 CAPLUS
 CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-49-1 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Rotation (-).




RN 357425-55-9 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-ol, 2,3,4,5-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-56-0 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-57-1 CAPLUS
 CN Pyrrolidine, 1-[(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)sulfonyl]-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-58-2 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro-, (-)- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 357425-50-4 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-51-5 CAPLUS
 CN 1,5-Methano-1H-3-benzazepin-7-amine, 2,3,4,5-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-52-6 CAPLUS
 CN Acetamide, N-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-53-7 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-54-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-, (-)- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Rotation (-).




RN 357425-59-3 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-60-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-ethynyl-2,3,4,5-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-61-7 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-chloro-2,3,4,5-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-62-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-chloro-8-ethynyl-2,3,4,5-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-63-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro-8-(trifluoromethyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-64-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-8-(trifluoromethyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-65-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-8-(trifluoromethyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-66-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-2,3,4,5-tetrahydro-8-(trifluoromethyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Rotation (-).




RN 357425-71-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-72-0 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-73-1 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-74-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-67-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-(trifluoromethyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-68-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-69-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 6-fluoro-2,3,4,5-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-70-8 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-75-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-76-4 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-77-5 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-one, 1,6,7,8,9,10-hexahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-78-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-79-7 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methoxy-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-80-0 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-5-fluoro-7,8,9,10-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-81-1 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-11-fluoro-7,8,9,10-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-82-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● 2 HCl

RN 357425-87-7 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


IT 357425-88-8P 357425-89-9P 357425-90-2P
357425-91-3P 357425-92-4P 357425-93-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl-fused azapolycyclic compds. as nicotine binding inhibitors)
RN 357425-88-8 CAPLUS
CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 357425-89-9 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● 2 HCl

RN 357425-83-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 357425-84-4 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 357425-86-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 357425-90-2 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 357425-91-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-5-fluoro-7,8,9,10-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 357425-92-4 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl

RN 357425-93-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 69718-72-5
CMF C11 H13 N



CM 2


CRN 104-15-4
CMF C7 H8 O3 S




IT 230615-52-8 357426-15-4 357426-16-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aryl-fused azapolycyclic compds. as nicotine binding inhibitors)
RN 230615-52-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


357426-10-9P 357426-13-2P 357426-17-6P
357426-18-7P 357426-19-8P 357426-20-1P
357426-21-2P 357426-22-3P 357426-23-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aryl-fused azapolycyclic compds. as nicotine binding inhibitors)
RN 230615-48-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 230615-50-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 230615-51-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-53-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-56-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-amine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 357426-15-4 CAPLUS
CN Ethanethioamide, 2,2,2-trifluoro-N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoro-1-thioethyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 357426-16-5 CAPLUS
CN 5,9-Methano-5H-thiazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




IT 230615-48-2P 230615-50-6P 230615-51-7P
230615-53-9P 230615-56-2P 230615-57-3P
230615-59-5P 230615-60-6P 230615-61-9P
230615-62-0P 230615-63-1P 230615-64-2P
230615-65-3P 230615-66-4P 230615-67-5P
230615-68-6P 230615-69-7P 230615-70-0P
230615-71-1P 230615-72-2P 230615-73-3P
230615-74-4P 230615-77-7P 230615-78-8P
230615-79-9P 230615-80-2P 230615-81-3P
230615-82-4P 230615-83-5P 230615-84-6P
230615-85-7P 230615-86-8P 230615-88-0P
230615-89-1P 230615-92-6P 230615-93-7P
357425-94-6P 357425-95-7P 357425-96-8P
357425-97-9P 357425-98-0P 357425-99-1P
357426-00-7P 357426-01-8P 357426-02-9P
357426-04-1P 357426-05-2P 357426-06-3P
357426-07-4P 357426-08-5P 357426-09-6P


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-57-3 CAPLUS
CN Acetamide, N-[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 230615-59-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7,8-dinitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-60-8 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7,8-dinitro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-61-9 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7,8-diamino-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 230615-62-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-63-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-1-propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-64-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-65-3 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-(butylamino)-1,2,4,5-tetrahydro-8-nitro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 1,5-Methano-1H-3-benzazepine-7,8-diamine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-70-0 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-71-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-ol, 2,3,4,5-tetrahydro-8-nitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-72-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-ol, 8-amino-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-73-3 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-66-4 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-amino-8-(butylamino)-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-67-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 1-butyl-5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-68-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-1-(2-methylpropyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-69-7 CAPLUS


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-74-4 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-77-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-iodo-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-78-8 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-iodo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-79-9 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-cyano-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 230615-80-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-acetyl-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-81-3 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-acetyl-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-82-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)-, acetate (ester) (9CI) (CA INDEX NAME)




RN 230615-83-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-84-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 8-acetyl-2,3,4,5-tetrahydro-3-


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-85-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-8-[1-(hydroxyimino)ethyl]-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-86-8 CAPLUS
CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-88-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-89-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonyl chloride, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-92-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-iodo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 230615-93-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-phenyl-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 357425-94-6 CAPLUS
CN Ethanethioamide, N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoro-1-thioethyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 357425-95-7 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 2-chloro-6,7,8,9-tetrahydro-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 357425-96-8 CAPLUS
CN Boronic acid, [2,3,4,5-tetrahydro-3-(phenylmethyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 357425-97-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 357425-98-0 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357425-99-1 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




Aryl Fused Azapolycyclic Compounds

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 357426-00-7 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-01-8 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-02-9 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-04-1 CAPLUS
CN Propanamide, 3,3-dimethoxy-N-[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 357426-05-2 CAPLUS


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
2-chloro-5-fluoro-6,7,9,10-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)




RN 357426-10-9 CAPLUS
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-13-2 CAPLUS
CN 1,5-Methano-2H-3-benzazepin-2-one, 1,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 357426-17-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 1-(2,2-dimethylpropyl)-5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




• HCl


RN 357426-18-7 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 1-(2,2-dimethylpropyl)-5,6,8,9-tetrahydro-2-methyl-, 1,1-dimethylethyl

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-06-3 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-07-4 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid, 2-chloro-6,7,9,10-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 357426-08-5 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid, 6,7,9,10-tetrahydro-2-methoxy-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 357426-09-6 CAPLUS
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid,

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
ester, monohydrochloride (9CI) (CA INDEX NAME)




• HCl

RN 357426-19-8 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine-8-carboxylic acid, 6,7,9,10-tetrahydro-2,3-dimethyl-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



• HCl


RN 357426-20-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carboximidamide, 2,3,4,5-tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 357426-21-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-[3-(dimethylamino)-1-oxo-2-propenyl]-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 357426-22-3 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-23-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-pyrrolidinylsulfonyl)-3-(trifluoroacetyl)-, monohydrochloride (9CI) (CA INDEX NAME)




• HCl


REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 230615-75-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 249296-44-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 287973-26-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-77-2 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 328055-78-3 CAPLUS
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



L22 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:152263 CAPLUS
DOCUMENT NUMBER: 134:198095
TITLE: Composition for the treatment and prevention of nicotine addiction containing a nicotine receptor agonist and an anti-depressant or anti-anxiety drug
INVENTOR(S): Coe, Jotham Wadsworth; Harrigan, Edmund Patrick; O'Neill, Brian Thomas; Sands, Steven Bradley
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1078637	A2	20010228	EP 2000-307254	20000823
EP 1078637	A3	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001072604	A2	20010321	JP 2000-254041	20000824
ZA 2000004406	A	20020225	ZA 2000-4406	20000825
US 2003109544	A1	20030612	US 2003-348399	20030121

PRIORITY APPLN. INFO.:
US 1999-151089P P 19990827
US 2000-578369 B1 20000525
US 2000-697749 A1 20001026

AB Pharmaceutical compns. are disclosed for the treatment of nicotine dependence or addiction, tobacco dependence or addiction, reduction of nicotine withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse. The pharmaceutical compns. are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an anti-depressant or anxiolytic agent and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.


IT 69718-72-5 230615-75-5 249296-44-4
287973-26-6 328055-77-2 328055-78-3
328055-79-4 328055-80-7 328055-81-8
328055-82-9 328055-83-0 328055-84-1
328055-85-2 328055-86-3 328055-87-4
328055-88-5 328055-89-6 328055-90-9
328055-92-1 328055-93-2 328055-94-3
328055-95-4 328055-96-5 328055-97-6
328055-98-7 328055-99-8 328056-66-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nicotine and other drug addiction treatment with compns. containing nicotine receptor agonists and antidepressants or anxiolytic agents)
RN 69718-72-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




L22 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 328055-79-4 CAPLUS
CN 5,9-Methanimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-80-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-81-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-82-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-ethynyl-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-83-0 CAPLUS
CN 5,9-Methano-2H-isothiazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




Aryl Fused Azapolycyclic Compounds

L22 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 328055-84-1 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)




RN 328055-85-2 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 328055-86-3 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro- (9CI) (CA INDEX NAME)




RN 328055-87-4 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)




RN 328055-88-5 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 328055-94-3 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-95-4 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-96-5 CAPLUS
 CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 328055-97-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 328055-98-7 CAPLUS
 CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)


L22 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328055-89-6 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)




RN 328055-90-9 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)




RN 328055-92-1 CAPLUS
 CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)




RN 328055-93-2 CAPLUS
 CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



L22 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 328055-99-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 328056-66-2 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-fluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




Aryl Fused Azapolycyclic Compounds

L22 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 ACCESSION NUMBER: 2000:553442 CAPLUS
 DOCUMENT NUMBER: 133:168383
 TITLE: Pharmaceutical compositions containing nicotine or a ligand of nicotine receptors and a monamine oxidase inhibitor and their use for treating tobacco withdrawal symptoms
 INVENTOR(S): Caille, Dominique; George, Pascal; Jegham, Samir; Robineau, Pascale; Scatton, Bernard; Zivkovic, Branimir
 PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.
 SOURCE: PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000045846	A1	20000810	WO 2000-FR193	20000128
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2788982	A1	20000804	FR 1999-1144	19990202
FR 2788982	B1	20020802		
EP 1150715	A1	20011107	EP 2000-901660	20000128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002536342	T2	20021029	JP 2000-596965	20000128
PRIORITY APPLN. INFO.: FR 1999-1144 A 19990202 WO 2000-FR193 W 20000128				

OTHER SOURCE(S): MARPAT 133:168383
 AB The invention concerns novel pharmaceutical compns. containing nicotine or a ligand of nicotine receptors and a monamine oxidase inhibitor designed for treating tobacco withdrawal symptoms. A bilayer tablet contained beflonaxone 5, lactose 66, microcryst. cellulose 20, povidone 4, crospovidone 4, and magnesium stearate 1% in the first layer, and nicotine polacrilex 5, microcryst. cellulose 20, povidone 4, hydroxypropyl Me cellulose 25, magnesium stearate 1, and lactose q.s. 100% in the second layer.
 IT 287973-24-4 287973-25-5 287973-26-6
 287973-27-7 287973-28-8 287973-29-9
 287973-32-4
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical compns. containing nicotine or ligand of nicotine receptors and monamine oxidase inhibitor and their use for treating tobacco


L22 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 287973-29-9 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 287973-32-4 CAPLUS
 CN 5,9-Methanopyrrolo[3,4-h][3]benzazepine-1,3(2H,5H)-dione, 5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L22 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 withdrawal symptoms)
 RN 287973-24-4 CAPLUS
 CN 5,9-Methanopyrrolo[3,4-h][3]benzazepine-1,3(2H,5H)-dione, 5,6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 287973-25-5 CAPLUS
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 287973-26-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 287973-27-7 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 8-ethynyl-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 287973-28-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:451282 CAPLUS
 DOCUMENT NUMBER: 131:102204
 TITLE: Preparation of 1,5-methano-3-benzazepines and analogs as nicotinic receptor ligands
 INVENTOR(S): Coe, Jotham Wadsworth; Brooks, Paige Roanne Palmer
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9935131	A1	19990715	WO 1998-1B1813	19981113
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2316921	AA	19990715	CA 1998-2316921	19981113
AU 9896416	A1	19990726	AU 1998-96416	19981113
AU 753389	B2	20021017		
BR 9814592	A	20001017	BR 1998-14592	19981113
EP 1044189	A1	20001018	EP 1998-950274	19981113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
TR 200001840	T2	20001221	TR 2000-200001840	19981113
JP 2002500218	T2	20020108	JP 2000-527532	19981113
NZ 504482	A	20030131	NZ 1998-504482	19981113
TW 513412	B	20021211	TW 1998-87121748	19981228
ZA 9811911	A	20000629	ZA 1998-11911	19981229
US 6410550	B1	20020625	US 1999-402010	19990928
US 6605610	B1	20030812	US 2000-514002	20000225
BG 104561	A	20010131	BG 2000-104561	20000627
NO 2000003422	A	20000829	NO 2000-3422	20000630
HR 2000000445	A1	20010430	HR 2000-445	20000630
US 2002072525	A1	20020613	US 2002-752543	20020213
US 2002072524	A1	20020613	US 2002-75348	20020214
US 2002111350	A1	20020815	US 2002-127267	20020422
US 2002132824	A1	20020919	US 2002-131278	20020423
US 2003130261	A1	20030710	US 2003-336508	20030103
US 2003130260	A1	20030710	US 2003-336532	20030103

PRIORITY APPLN. INFO.:
 US 1997-70245P P 19971231
 WO 1998-1B1813 W 19981113
 US 1999-402010 A2 19990928
 US 2000-514002 A1 20000225

OTHER SOURCE(S): MARPAT 131:102204
 GI

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB Title compds. [I; R1 = H, alk(en)yl, alkoxyethyl, oxoalkyl, etc.; R2,R3 = H, halo, (di)alkylamino, alkyl, etc.; R2R3 = atoms to complete a ring] were prepared. Thus, 2-FCGH4Br was cyclocondensed with cyclopentadiene and the product osmylated to give 1,2,3,4-tetrahydro-1,4-methanonaphthalene-2,3-diol which was treated with NaIO4 and the product cyclocondensed with PhCH2NH2 to give, after deprotection, I (R1-R3 = H). Data for biol.


activity of I were given.
 IT 69718-72-5P 230614-99-0P 230615-00-6P
 230615-01-7P 230615-02-8P 230615-03-9P
 230615-04-0P 230615-05-1P 230615-06-2P
 230615-07-3P 230615-08-4P 230615-09-5P
 230615-10-6P 230615-11-9P 230615-12-0P
 230615-13-1P 230615-14-2P 230615-15-3P
 230615-16-4P 230615-17-5P 230615-18-6P
 230615-19-7P 230615-20-0P 230615-21-1P
 230615-22-2P 230615-23-3P 230615-24-4P
 230615-25-5P 230615-26-6P 230615-27-7P
 230615-28-8P 230615-29-9P 230615-30-2P
 230615-31-3P 230615-32-4P 230615-33-5P
 230615-34-6P 230615-35-7P 230615-36-8P
 230615-37-9P 230615-38-0P 230615-39-1P
 230615-40-4P 230615-41-5P 230615-42-6P
 230615-43-7P 230615-44-8P 230615-45-9P
 230615-46-0P 230615-52-8P 230615-75-5P
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1,5-methano-3-benzazepines and analogs as nicotinic

receptor ligands)
 RN 69718-72-5 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 230614-99-0 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-03-9 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 6-fluoro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-04-0 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-05-1 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 7-amino, 2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl

RN 230615-00-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-01-7 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-02-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-06-2 CAPLUS
 CN Acetamide, N-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-07-3 CAPLUS
 CN 5,9-Methano-5H-thiazolo[4,5-b][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-08-4 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7,8-dinitro- (9CI) (CA INDEX NAME)



RN 230615-09-5 CAPLUS
 CN 5,9-Methanoimidazo[4,5-b][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-10-8 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-11-9 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-12-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-16-4 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-17-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-18-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-13-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-14-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-15-3 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-19-7 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-20-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-1,5,6,7,8,9-hexahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-21-1 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-22-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-23-3 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-24-4 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-25-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-26-6 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-27-7 CAPLUS
CN Benzamide, 2-fluoro-N-(2,3,4,5-tetrahydro-8-hydroxy-1,5-methano-1H-3-benzazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl

RN 230615-28-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-29-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-30-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-31-3 CAPLUS
CN Ethanone, 1-(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-32-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-33-5 CAPLUS
CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-34-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-5-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-35-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-methyl-1H-pyrazol-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-36-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-40-4 CAPLUS
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-41-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-42-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 6-ol, 2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




● HCl

RN 230615-37-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-38-0 CAPLUS
CN Pyrrolidine, 1-[(2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepin-7-yl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-39-1 CAPLUS
CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-43-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-difluoro-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-44-8 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 2-ethyl-6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-45-9 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Aryl Fused Azapolycyclic Compounds

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl

RN 230615-46-0 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-52-8 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 230615-75-5 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, (9CI) (CA INDEX NAME)




L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-nitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-54-0 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-nitro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-55-1 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-amino-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-56-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-3-carboxylic acid, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-57-3 CAPLUS
CN Acetamide, N-[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)


L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

IT 230615-48-2P 230615-50-6P 230615-51-7P
230615-53-9P 230615-54-0P 230615-55-1P
230615-56-2P 230615-57-3P 230615-58-4P
230615-59-5P 230615-60-8P 230615-61-9P
230615-62-0P 230615-63-1P 230615-64-2P
230615-65-3P 230615-66-4P 230615-67-5P
230615-68-6P 230615-69-7P 230615-70-0P
230615-71-1P 230615-72-2P 230615-73-3P
230615-74-4P 230615-76-6P 230615-77-7P
230615-78-8P 230615-79-9P 230615-80-2P
230615-81-3P 230615-82-4P 230615-83-5P
230615-84-6P 230615-85-7P 230615-86-8P
230615-87-9P 230615-88-0P 230615-89-1P
230615-90-4P 230615-92-6P 230615-93-7P
230615-94-8P 230615-95-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1,5-methano-3-benzazepines and analogs as nicotinic


receptor ligands)
RN 230615-48-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 230615-50-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-fluoro-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 230615-51-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-53-9 CAPLUS


L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-58-4 CAPLUS
CN Ethanethioamide, N-[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 230615-59-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7,8-dinitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-60-8 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7,8-dinitro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-61-9 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7,8-diamino-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Aryl Fused Azapolycyclic Compounds


L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-62-0 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-63-1 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-1-propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-64-2 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-65-3 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-(butylamino)-1,2,4,5-tetrahydro-8-nitro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 230615-69-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7,8-diamine, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-70-0 CAPLUS
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-71-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-ol, 2,3,4,5-tetrahydro-8-nitro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-72-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-ol, 8-amino-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-73-3 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-66-4 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-amino-8-(butylamino)-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-67-5 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 1-butyl-5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-68-6 CAPLUS
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-1-(2-methylpropyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-74-4 CAPLUS
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-76-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-chloro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-77-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-iodo-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-78-8 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-iodo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




Aryl Fused Azapolycyclic Compounds

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 230615-79-9 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-cyano-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-80-2 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7-acetyl-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-81-3 CAPLUS
CN 1,5-Methano-3H-3-benzazepine-3-carboxylic acid, 7-acetyl-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-82-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)-, acetate (ester) (9CI) (CA INDEX NAME)




RN 230615-83-5 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)-


L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-88-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 7,8-dichloro-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-89-1 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-sulfonyl chloride, 2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-90-4 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-7-(1-pyrrolidinylsulfonyl)-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-92-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-iodo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(9CI) (CA INDEX NAME)




RN 230615-84-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 8-acetyl-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-85-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-8-[1-(hydroxyimino)ethyl]-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-86-8 CAPLUS
CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-87-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-7-propanamine, 2,3,4,5-tetrahydro-N,N-dimethyl-γ-oxo-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 230615-93-7 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-6-phenyl-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 230615-94-8 CAPLUS
CN Boronic acid, [2,3,4,5-tetrahydro-3-(phenylmethyl)-1,5-methano-1H-3-benzazepin-6-yl]- (9CI) (CA INDEX NAME)



RN 230615-95-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepin-6-ol, 2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1989:423537 CAPLUS
 DOCUMENT NUMBER: 111:23537
 TITLE: Preparation of psychotropic N-(piperazinylalkyl) polycyclic imides
 INVENTOR(S): Stack, Gary Paul; Golobish, Thomas David; Abou-Gharbia, Magid Abdel Megid
 PATENT ASSIGNEE(S): American Home Products Corp., USA
 SOURCE: Eur. Pat. Appl., 19 pp.
 CODEN: EPXXOW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 286263	A1	19881012	EP 1988-302499	19880322
EP 286263	B1	19910515		
R: AT, BE, CH, DE, ES, FR, GR, IT, LI, LU, NL, SE				
US 4797488	A	19890110	US 1987-34820	19870403
CA 1306251	A1	19920811	CA 1988-561882	19880318
GB 2203428	A1	19881019	GB 1988-6778	19880322
GB 2203428	B2	19910331		
AT 63551	E	19910615	AT 1988-302499	19880322
ES 2039617	T3	19931001	ES 1988-302499	19880322
AU 8813512	A1	19881006	AU 1988-13512	19880323
AU 597480	B2	19900531		
WO 8807529	A1	19881006	WO 1988-US973	19880331
W: DK, JP, KR				
JP 01502756	T2	19890921	JP 1988-503414	19880331
US 4824999	A	19890425	US 1988-248769	19880923
DK 8806738	A	19881202	DK 1988-6738	19881202
AU 9051158	A1	19900628	AU 1990-51158	19900308
AU 617930	B2	19911205		
PRIORITY APPLN. INFO.:				
		US 1987-34820	19870403	
		EP 1988-302499	19880322	
		WO 1988-US973	19880331	
OTHER SOURCE(S): CASREACT 111:23537; MARPAT 111:23537				
GI				

L22 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The title compds. [I: R = (halo)-2-pyrimidinyl, (halo)pyrazinyl, (halo)quinolinyl, (un)substituted Ph, pyridinyl; R1R2 = C3-5 alkylene, C3-5 alkenylene, polycyclic alkanediyl moiety Q, Q1, atoms to complete a fused benzo ring; X = R3R4C, S, SO, 6O2; R3, R4 = H, C1-4 alkyl; R3R4 = C2-4 alkylene; Y = CH2, CH2CH2, O, S; n = 2-5; dotted line represents optional double bond] and their pharmaceutically acceptable salts were prepared as psychotropic agents, useful as antipsychotics and anxiolytics. Bicyclo[3.3.0]octane-2,4-dicarboxylic acid was refluxed 3 h in Ac2O to give its anhydride which was refluxed 48 h with 1-(4-aminobutyl)-4-(trifluoromethyl)piperazine in xylene to give, after acidification, methanocyclopentazepinedione II. In rats, II inhibited the conditioned avoidance response with an ED50 of 46.17 mg/kg orally and inhibited apomorphine-induced stereotypy and climbing behavior with ED50 of 42.37 and 18.89 mg/kg orally, resp.


IT 121305-54-2P 121305-55-3P 121305-69-9P 121305-70-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as antipsychotic)

RN 121305-54-2 CAPLUS


CN 1,5-Methano-1H-3-benzazepine-2,4(3H,5H)-dione, 3-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

L22 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 121305-55-3 CAPLUS

CN 1,5-Methano-1H-3-benzazepine-2,4(3H,5H)-dione, 3-[4-[4-(6-chloropyrazinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



RN 121305-69-9 CAPLUS


CN 1,5-Methano-1H-3-benzazepine-2,4(3H,5H)-dione, 3-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 121305-70-2 CAPLUS


CN 1,5-Methano-1H-3-benzazepine-2,4(3H,5H)-dione, 3-[4-[4-(6-chloropyrazinyl)-1-piperazinyl]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1979:432639 CAPLUS
 DOCUMENT NUMBER: 91:32639
 TITLE: Synthesis and pharmacological activity of
 2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepines
 AUTHOR(S): Mazzocchi, Paul H.; Stahly, Barbara C.
 CORPORATE SOURCE: Dep. Chem., Univ. Maryland, College Park, MD, USA
 SOURCE: Journal of Medicinal Chemistry (1979), 22(4), 455-7
 CODEN: JMCMDR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 91:32639
 GI




AB The title compds. I (R = H, alkyl, allyl, etc.) were prepared from
 2,3-dioxobenzonorborene. 3-Allyl-2,3,4,5-tetrahydro-1,5-methano-1H-3-
 benzazepine oxalate (1:1) showed a slight antinociceptive activity in the
 mouse hot-plate assay and little antagonistic activity in the tail-flick
 assay. None of other I showed significant analgesic activity and all
 except 2,3,4,5-tetrahydro-3-(2-phenylethyl)-1,5-methano-1H-3-benzazepine
 oxalate (1:1) were toxic. Structure-activity relations are discussed.
 IT 69718-72-5P
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and alkylation of)
 RN 69718-72-5 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



IT 69718-73-6P 69718-78-1P 69718-80-5P
 69718-83-8P 69718-85-0P 69718-87-2P
 69718-89-4P
 RI: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and analgesic and narcotic antagonist activities of)
 RN 69718-73-6 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-, ethanedioate (1:1)
 (9CI) (CA INDEX NAME)
 CM 1
 CRN 69718-72-5
 CMF C11 H13 N


L22 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CMF C19 H21 N



CM 2
 CRN 144-62-7
 CMF C2 H2 O4



RN 69718-83-8 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-,
 ethanedioate (1:1) (9CI) (CA INDEX NAME)
 CM 1
 CRN 69718-82-7
 CMF C15 H19 N



CM 2
 CRN 144-62-7
 CMF C2 H2 O4



RN 69718-85-0 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-propyl-, ethanedioate
 (1:1) (9CI) (CA INDEX NAME)
 CM 1
 CRN 69718-84-9
 CMF C14 H19 N

L22 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




CM 2
 CRN 144-62-7
 CMF C2 H2 O4



RN 69718-78-1 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-methyl-, ethanedioate
 (1:1) (9CI) (CA INDEX NAME)

CM 1
 CRN 69718-77-0
 CMF C12 H15 N




CM 2
 CRN 144-62-7
 CMF C2 H2 O4



RN 69718-80-5 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-(2-phenylethyl)-,
 ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1
 CRN 69718-79-2

L22 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




CM 2
 CRN 144-62-7
 CMF C2 H2 O4



RN 69718-87-2 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-(2-propenyl)-,
 ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1
 CRN 69718-86-1
 CMF C14 H17 N



CM 2
 CRN 144-62-7
 CMF C2 H2 O4




RN 69718-89-4 CAPLUS
 CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-(3-methyl-2-butenyl)-,
 ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1
 CRN 69718-88-3
 CMF C16 H21 N

Aryl Fused Azapolycyclic Compounds

L22 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




CM 2


CRN 144-62-7
CMF C2 H2 O4



IT 69718-76-9P 69718-81-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
RN 69718-76-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine-2,4(3H,5H)-dione (9CI) (CA INDEX NAME)




RN 69718-81-6 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 3-(cyclopropylcarbonyl)-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



IT 69718-77-0P 69718-84-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 69718-77-0 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)

L22 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 69718-84-9 CAPLUS
CN 1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-propyl- (9CI) (CA INDEX NAME)

